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ABSTRACT   
 
The 37kDa/67kDa laminin receptor (LRP/LR) is thought to play a major role in the 
adhesion to laminin and consequently invasion resulting in the metastasis of tumor 
cells. This receptor is reported to be over-expressed in several neoplastic cell lines 
and is believed to increase tumor aggressiveness. This research aims at determining 
whether the application of anti-LRP/LR specific antibody (IgG1-iS18) on neoplastic 
cell lines would result in a decrease in invasion and adhesion. All neoplastic cell lines 
had significantly increased cell surface LRP/LR levels compared to NIH/3T3 cells, 
with the most notable increase seen in SW480 cells (10.98%). Due to a positive 
correlation between the cell surface LRP/LR levels and invasion potential we propose 
that an increased LRP/LR level correlates to an increased ability to invade. A 
significantly decreased adhesion potential was noted in all neoplastic cell lines except 
the non-invasive MCF-7 cell line, upon application of IgG1-iS18, 21% decrease in 
HT-1080 cells, 14% in HeLa, 20% in LNCaP, 48% and 74% in A549 and SW480 
cells, respectively. Incubation with the anti-LRP/LR antibody IgG1-iS18 resulted in a 
significant reduction of the invasive potential of HT-1080 (44%), A549 (33%), HeLa 
(69%), SW480 (91%) and LNCaP cells (38%). Furthermore, a high Pearson’s 
correlation coefficient between adhesion potential and invasive potential was seen, 
confirming that adhesion is indeed a pre-requisite for invasion. The significant 
reduction in invasion and adhesion of HT-1080, A549, HeLa, SW480 and LNCaP 
cells upon application of the IgG1-iS18 antibody suggests that this macromolecule 
might act as a promising therapeutic tool for the treatment of various metastatic 
cancer types.  
  iv 
ACKNOWLEDGEMENTS     
I would like to thank Prof. S. F. T. Weiss for giving me this wonderful opportunity 
and also for all his advice, guidance and time, ensuring that my project was a success 
and my results submitted for publication. 
 
For financial aid, I would like to acknowledge the University of the Witwatersrand for 
the Postgraduate Merit Award Scholarship and the National Research Foundation of 
South Africa for the Prestigious and Equity Scholarship.   
 
Antibody was kindly supplied by Affimed Therapeutics, Heidelburg, Germany.  
 
A special thanks to all the members of the Weiss laboratory, Dr. Vusi Mbazima 
whose assistance was invaluable. My lovely ladies Bianca Da Costa Dias, Kianshanee 
Moodley, Danielle Gonsalves and Raksha Khusal, who I will always share fond 
memories with and made time in the laboratory and the study room amazing and fun! 
 
Words cannot describe my appreciation for the support and motivation I received 
from my dearest friend Katarina Jovanovic who always had faith in me. Without your 
help this work would not have been possible, your optimism and inspiration kept me 
going and I will always be grateful for this. 
 
Last but not least I would like to thank my parents for all the prayers and for cheering 
me on, and my partner and best friend Zaheer ‘Boo’ Abdulla  for his words of 
encouragement. Love you lots!  
 
  v 
RESEARCH OUTPUT  
 
1. Original publications: 
 
- Omar A, Reusch U,  Knackmuss S, Little M and Weiss S. F. T. (2012). Anti-
LRP/LR specific antibody IgG1-iS18 significantly reduces adhesion and 
invasion of metastatic lung, cervix, colon and prostate cells. Journal of 
Molecular Biology 419: 102-109.  
 
- Kolodziejczak D, Da Costa Dias B, Zuber C, Jovanovic K, Omar A, Beck J, 
Vana K, Mbazima V, Richt J, Brenig B and Weiss S. F. T. (2010). Prion 
Interaction with the 37-kDa/67-kDa Laminin Receptor on Enterocytes as a 
Cellular Model for Intestinal Uptake of Prions. Journal of Molecular Biology 
402: 293-300. 
  
2. Reviews:  
 
- Omar A, Jovanovic K, Da Costa Dias B, Gonsalves D, Moodley  K, Caveny 
R, Mbazima V and Weiss S. F. T. (2011). Patented biological approaches for 
the therapeutic modulation of the 37kDa/67kDa laminin receptor. Expert 
Opinion on Therapeutic Patents 21(1):35-53.  
 
- Mbazima V, Da Costa Dias B, Omar A, Jovanovic K and Weiss S. F. T. 
(2010). Interactions between PrP(c) and other ligands with the 37-kDa/67-kDa 
laminin receptor. Frontiers in Biosciences 15: 1150-1163. 
 
 
 
3. Conference contributions:  
Poster presentations 
 
-    Omar A, Moodley K, Khusal R and Weiss  S. F. T. Anti-LRP/LR specific 
antibodies significantly reduces cell adhesion and cell viability of various 
metastatic cancer types. Cell and Developmental Biology Mini Symposium at 
The University of the Witwatersrand Medical School, 22 May 2011.  
 
-    Omar A, Knackmuss S, Reusch U, Little M and Weiss S. F . T. Anti-LRP/LR 
specific antibody IgG1-iS18 significantly reduced cell adhesion and cell 
invasion of various metastatic cancer types. Molecular Biology Research 
Thrust (MBRT) conference at The University of the Witwatersrand 
Postgraduate Development Hub, 7 December 2011.  
 
-    Omar A, Knackmuss S, Reusch U, Little M and Weiss S. F . T. Anti-LRP/LR 
specific antibody IgG1-iS18 significantly reduced cell adhesion and cell 
invasion of various metastatic cancer types.South African Society of 
Biochemistry and Molecular Biology Congress at Champagne Sports Resort,  
Drakensberg, KwaZulu-Natal, 29 January 2012.  
  vi 
LIST OF FIGURES   
Figure 1:  Percentage of deaths attributed to cancer     2 
Figure 2:  Comparison of normal and tumour cell division/proliferation 4 
Figure 3:  The 37kDa Laminin Receptor Precursor molecule    5 
Figure 4: Illustration of the process of metastasis    8 
Figure 5:  Electron micrograph of HT-1080 cell migration    8 
Figure 6:  Schematic diagram illustrating cell invasion     9 
Figure 7:  Illustration of a full length Immunoglobulin    10 
Figure 8: Principle of invasion assay       27 
Figure 9: Principle of adhesion assay       29 
Figure 10: Principle of semi-dry Transfer Western Blotting method  31 
Figure 11: Immuno-detection of proteins      32 
Figure 12:  Biochemical analysis of antibodies that were over-expressed 34 
Figure 13: Western Blot detection 37kDa LRP using antibody produced  35 
Figure 14: Detection of 37kDa LRP on surface of cell lines    37 
Figure 15: Bar chart of surface LRP levels      38 
Figure 16: Western Blot of total LRP levels      39 
Figure 17: Bar chart of total LRP levels       40 
Figure 18: Bar chart of adhesion assay results     42 
Figure 19:  Bar chart of neoplastic cell lines invasive potential    44 
Figure 20: Bar chart of effect of antibodies on HT-1080 cells   46 
Figure 21: Bar chart of effect of antibodies on HeLa cells   46 
Figure 22: Bar chart of effect of antibodies on A549 cells    47 
Figure 23: Bar chart of effect of antibodies on LNCaP cells    47 
Figure 24: Bar chart of effect of antibodies on SW480 cells    48 
Figure 25: Representative photographs of invasion assay results   49 
 
 
 
 
 
  vii 
LIST OF TABLES  
 
Table 1:  Characterization of cancer stages      3 
Table 2: Currently available monoclonal antibodies for cancer treatment  12 
Table 3:  Bacterial strains used in antibody production    15 
Table 4:  Cell lines used for in vitro experiments     16 
Table 5: Storage solutions used for freezing cell lines    17 
Table 6:  Solutions used in SDS-PAGE     20 
Table 7: Solutions used in Western Blotting      20 
Table 8: Solutions used in IgG purification     21 
Table 9: Antibodies used in the various experiments     21 
Table 10: Percentage reduction in adhesion potential     42 
Table 11: Tumorigenic cell lines invasive behavior and potential   44 
Table 12: Summary of invasion assay results      48 
Table 13:  Pearson’s correlation coefficient values       53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  viii 
ABBREVIATIONS   
aa    Amino acid         
AAV    Adeno associated virus 
ADC’s   Antibody drug conjugates 
APS    Ammonium peroxisulfate 
BCA    Bicinchonic acid 
C-terminus   Carboxy terminus 
CTLA-4   Cytotoxic T-lymphocyte Antigen 4 
DPBS   Dulbecco’s phosphate buffer solution  
DMEM   Dulbecco’s modified eagle media 
DMSO   Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
DOC    Deoxycholic acid 
DTT    Dithioreitol 
E.R    Endoplastic reticulum 
EBV    Ebstein Barr Virus 
EBNA   Ebstein Barr nuclear antigen      
ECM    Extracellular matrix 
EDTA   Ethylenediaminetetracetic acid 
EHS    Engelbreth-Holm-Swarm 
EpCAM   Epithelial cell adhesion molecule 
ErbB2   Erythroblastic leukemia viral oncogene homolog 2 
FACS   Fluorescent activated cell scanning 
FCS    Fetal calf serum 
FITC    Fluorescein isothiocynate 
HC    Heavy chain 
Hep3B   Human hepatoma cells  
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HM2602   Heparan sulfate mimetic 2602 
HRP    Horse radish peroxidase 
IgG    Immunoglobulin 
IgG1-iS18    Immunoglobulin G 1 iS18 
IOD    Integrated optical density 
  ix 
ITS    Insulin transferrin selenium 
LB    Luria bertani 
LC    Light chain 
LRP    Laminin receptor precursor  
LR    Laminin receptor 
MAb’s   Monoclonal antibodies 
MAPK   Mitogen activated protein kinase  
MMP   Matrix metalloproteinase 
MRI    Magnetic resonance imaging 
MWCO   Molecular weight cut-off 
N-terminus   Amino terminus 
P4G    Anti-LRP antibody 
p53     Tumor protein 53 
PBS    Phostphate buffered saline 
PFA    Paraformaldehyde 
POD    Peroxidase 
PVDF   Polyvinylidene fluoride 
RNA    Ribonucleic acid 
RPMI 1640  Roswell Park Memorial Institute media 
ScFv IgG   Single chain variable fragment immunoglobulin G 
SDS    Sodium dodecylsulfate 
SDS-PAGE  Sodium dodecylsulfate polyacrylamide gel electrophoresis 
siRNA    Single interfering ribonucleic acid 
SP-54   Pentosan sulfate 54 
TC    Tissue culture  
TE    Tris EDTA  
TEMED   N, N, N’, N’ - tetramethylethylenediamine 
TGF-ß   Transforming growth factor ß 
VEE    Venezuelan equine encephalitis virus     
VEGF   Vascular endothelial growth factor  
 
     
CONTENTS                        PAGE 
DECLARATION  II 
ABSTRACT  III 
ACKNOWLEDGEMENTS  IV 
RESEARCH OUTPUT  V 
LIST OF FIGURES  VI 
LIST OF TABLES  VII 
ABBREVIATIONS  VIII 
CHAPTER ONE – INTRODUCTION  1 
1.1 Cancer  1 
1.2 Classification of cancer  2 
1.3 Progression of cancer  3 
1.4 Laminin  4 
1.5 LRP/LR  5 
1.6 The 37kDa/67kDa LRP/LR and cancer  6 
1.7 Antibodies  10 
1.8 Therapeutic antibodies  11 
1.9 Anti­LRP/LR specific antibody IgG1­iS18  13 
1. 10 Aims and objectives  14 
CHAPTER TWO – MATERIALS  15 
2.1. Molecular biology  15 2.1.1 Plasmids  15 2.1.2 Bacterial strains  15 
2.2 Cell culture  16 2.2.1 Eukaryotic cell lines  16 2.2.2 Cell culture media  16 2.2.3 Cell culture material  18 2.2.4 Material for cell lysates  18 2.2.5 Material for transient transfection  18 2.2.6 Material for invasion and adhesion assays  19  
 2.3 Protein biochemistry  20 2.3.1. Solutions and reagents  20 2.3.2. Antibodies  21 
CHAPTER THREE – METHODS  22 
3.1. Molecular biology  22 3.1.1 Plasmid DNA isolation  22 
3.2. Cell culture  22 3.2.1 Cell cultivation  22 3.2.2 Freezing and thawing of cells  22 3.2.3 Cell count determination  23 3.2.4 Preparation of cell lysates  23 3.2.5 BCA™ protein assay  23 
3.3 Antibody production  24 3.3.1 Synthesis of IgG1‐iS18 and IgG1‐HD37 in mammalian cells  24 3.3.2 Purification of IgG1‐iS18 and –HD37 by protein A sepharose affinity chromatography  24 3.3.3 Dialysis of IgG1‐iS18 and IgG1‐HD37  25 3.3.4 Detection of IgG1‐iS18 and IgG1‐HD37  25 3.3.5 Quantification of IgG1‐iS18 and IgG1‐HD37  25 
3.4 FACS (Fluorescence activated cell scanning)  26 
3.5 Invasion assays  27 3.5.1 Preparation of Transwell inserts, cells and determination of invasive potential  28 
3.6 Adhesion assay  29 
3.7 Protein Biochemistry  30 3.7.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE)  30 3.7.2 Western Blotting  30 3.7.3 Protein detection and chemiluminescence  31 
3.8 Data analysis and statistical evaluation  32 
CHAPTER FOUR – RESULTS  33 
4.1 Production of anti­LRP/LR specific antibody IgG1­iS18 in mammalian cells  33 4.1.1 Characterization of the plasmids  33 4.1.2 Antibody over‐expression in HEK293 EBNA cells  33 4.1.3 Purification and detection of IgG1‐iS18 and IgG1‐HD37  34 4.1.4 Dialysis of IgG1‐iS18 and IgG1‐HD37  35 4.1.5 Characterization of IgG1‐iS18  35 
4.2 LRP levels  36 4.2.1 Cell surface LRP levels  36 4.2.2 Total LRP levels  39 
4.3 Cell adhesion potential  41 
4.4 Invasive potential  43 4.4.1 Determination of cell invasive potential of selected neoplastic cell lines  43 4.4.2 IgG1‐iS18 significantly decreased the invasive potential in neoplastic cell lines  45 
 CHAPTER FIVE – DISCUSSION  50 
5.1 Antibody development  50 
5.2 Process of metastasis  51 
5.3 LRP/LR, cell surface LRP and total LRP levels  51 
5.4 Surface and total LRP levels appear not to be an accurate indication of invasive 
potential  53 
5.5 Optimizing invasion assay  53 
5.6 Effect of IgG1­iS18 antibody on invasion and adhesion  54 
5.7 Antibody activity  55 
5.8 Outlook  55 
6. REFERENCES  57 
7. APPENDIX  62 
  1 
CHAPTER ONE – INTRODUCTION  
1.1 Cancer    
Cancer is one of the leading causes of mortality globally and was found to be 
responsible for approximately 13% of all deaths worldwide in 2007 
(http://www.who.int/cancer/en/.  Retrieved  March  4,  2010). Predictions have 
shown an increased mortality rate resulting from this disease with an estimated 12 
million deaths by 2030 (http://www.who.int/cancer/en/.  Retrieved  March  4, 2010). The most striking feature of this disease is that it affects people of all ages, 
races, genders and economic statuses. According to the World Health Organization 
the most frequent cancer types that occur in both sexes worldwide are, in order of 
decreasing incidence rate, breast cancer, prostate cancer, lung cancer, colorectal 
cancer and cervix uteri cancer (GLOBOCAN 2008 (IARC)). The most common 
cancer types occurring in the Western World include lung, breast, prostate and colon 
cancers (http://info.cancerresearchuk.org.  Retrieved  March  4,  2010). However, 
this differs with newly industrialized countries where the prominent cancer types 
include cervix and stomach cancer (Figure 1).  This variance is due to progress in 
diagnostic techniques, which is often unaffordable to those in poorer regions. Early 
diagnosis is possible with the help of techniques such as magnetic resonance imaging 
(MRI) and leads to an overall decrease in mortality. Another aspect that plays an 
influential role in reducing the number of fatalities includes the discovery, and 
consequently, the spread of awareness regarding risk factors for cancer. Currently, 
several modes of treatment are available such as surgery, chemotherapy, radiation 
therapy, immunotherapy and monoclonal antibody therapy. Other novel approaches 
include gene therapy1, non-pathogenic bacteria and telomerase therapy2. In cases 
when the tumor becomes metastatic, treatment becomes challenging since various 
tissues are affected.    
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Figure 1: Estimated deaths per 100 000 population by cause in 2004, South Africa3.   
1.2 Classification of cancer   
Cancers are classified according to the type of cell that constitute the tumor, and 
hence the assumed origin of the tumor, histology and the extent of the disease 
(http://www.oncologychannel.com/staging.shtml#staging,  Retrieved  May  22, 2010). This classification would aid in determining appropriate treatment as well as 
provide a more accurate prognosis 
(http://www.oncologychannel.com/staging.shtml#staging.  Retrieved  May  22, 2010). The type of tissue in which the cancer first occurs could vary from 
adenocarcinoma (affecting glandular tissue) to blastoma (affecting embryonic tissue 
of organs), leukemia (affecting tissue that forms blood cells), lymphoma (lymphatic 
tissue), myeloma (originating from bone marrow), carcinoma (malignant tumors 
derived from epithelial cells) or even sarcoma (originating from connective or 
supportive tissue) (http://www.oncologychannel.com/staging.shtml#staging. 
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Retrieved  May  22,  2010). The extent of the disease is classified by the TNM 
method, tumour size (T), degree of node involvement (N) and distant metastasis (M) 
(http://www.oncologychannel.com/staging.shtml#staging.  Retrieved  May  22, 2010). A tumor given a M0 would suggest that no evidence of distant metastases has 
been noted while M1 would mean that distant metastasis is present. This can then be 
taken a step further with a numerical system providing a more detailed description of 
the extent of the disease (Table 1). 
  
Table 1:Table showing the stages of cancer with stage IV correlating to a poor prognosis 
 Stage 0  Cancer in situ (limited to surface cells) 
 Stage I  Cancer limited to the tissue of origin, evidence of tumor growth 
 Stage II  Limited local spread of cancerous cells 
 Stage III  Extensive local and regional spread 
 Stage IV  Distant metastasis 
The key factors that distinguish malignant tumors from benign tumors include the 
ability to infiltrate surrounding tissue, the destructive nature of the cells as well as its 
highly metastatic potential.  
1.3 Progression of cancer    
Cancer is a disease whereby mutations result in uncontrolled cell growth by either 
unregulated cell proliferation or the lack of apoptosis. These cells then continue to 
grow and mutate with the aid of oncogenes (e.g. Ras) or tumor suppressor genes (e.g. 
p53 and Rb) that act by altering cell cycle checkpoint regulators and the DNA repair 
system4.  
 
It has been shown that changes in the general apoptotic process could have a 
significant effect on the progression of tumors, suggesting the inactivation of 
apoptosis at the time of tumor progression4. It is suspected that most cancer types are 
able to induce changes that allow for the evasion of apoptosis (Figure 2). Mutations in 
p53 leads to uncontrolled cell proliferation4. Loss of pro-apoptotic (e.g. Bax genes) 
regulation occurs as a result of this mutation. Small interfering RNAs (siRNAs) 
directed against LRP/LR lead to the down-regulation of LRP/LR which in turn lead to 
the induction of apoptosis in Hep3B cancer cells5. This suggests that LRP/LR may 
  4 
play a role in cancer cell survival and may be a potential target for the induction of 
apoptosis in cancerous cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Comparison of normal and tumour cell division/proliferation. Healthy cells are 
displayed in grey and tumor cells in yellow. With the activation of oncogenes apoptosis is 
evaded and the tumor progresses. Non-oncogenic mutations induce apoptosis and allow for 
the continued proliferation of healthy cells3.   
1.4 Laminin 
The Extracellular Matrix (ECM) provides structural support and is the defining 
feature of connective tissue. It comprises of an interstitial matrix but more importantly 
the basement membrane, which consists of the basal laminae and the reticular 
laminae. One of the primary components of the ECM is laminin, predominantly found 
in the basal laminae is known to form web-like networks and plays a critical role in 
cell adhesion as well in the binding of several other ECM components. Laminin was 
found to be involved in the assembly of the basement membrane6, cell attachment7, 
migration8, growth9, differentiation and angiogenesis10. Laminin has also been 
implicated in the induction of increased MMP2 activity. The interaction between 
laminin and cells by means of the 67kDa laminin receptor plays a critical role in 
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signal transduction pathways as well as possible involvement in kinase phosphatase 
cascades.  
1.5 LRP/LR   
The 37kDa / 67kDa laminin receptor precursor/high affinity laminin receptor 
(LRP/LR) is believed to play a significant role during cell invasion and therefore in 
the metastasis of various cancer types3,11,12.  Several isoforms of the receptor have 
been found, with the most abundant being the 67kDa, which has a high affinity for 
laminin3. This receptor was first isolated from tumor cells13 and offers two binding 
sites for laminin, a peptide G sequence (aa161-180) and another at the carboxy 
terminus (aa205-229). Furthermore, this protein acts as a receptor for the cellular 
prion protein (PrPc)14, infectious prion protein (PrPSc)15, as well as some viruses such 
as Venezuelan equine encephalitis (VEE)16, Dengue virus, Sindbis virus17 and Adeno-
associated virus (AAV) serotypes 8, 2, 3 and 918. LRP/LR also provides binding sites 
for other extracellular components such as elastin and several carbohydrates19. Due to 
LRP/LR spanning the lipid bilayer as well as having the C-terminus situated in the 
extracellular space and a cytoplasmic N-terminus, it can be classified as a type II 
transmembrane protein (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: 37kDa laminin receptor precursor (LRP) on the cell surface showing the 
transmembrane domain in orange. It also shows the laminin/PrP binding domain in green, 
heparin/laminin binding domain in purple as well as the scFv/IgG1 antibody binding site 
indicated in pink, all of which form part of the receptor that is located in the extracellular 
space.  
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1.6 The 37kDa/67kDa LRP/LR and cancer 
LRP/LR is a non-integrin laminin receptor that is involved in several tumorigenic 
processes, in particular, cell proliferation, cell viability, cell movement, cell adhesion   
and cell attachment20. The degree of metastasis of neoplastic cells is highly dependant 
on the interaction with LRP/LR, this in turn affects the general laminin mediated 
basement attachment and consequently, local cell degradation and movement21. 
Expression of the mature 67kDa form of the receptor is found on most normal cells, 
the immature 37kDa form has been noted as being an oncofetal antigen. A direct link 
between the over-expression of the 67kDa form and an increased invasiveness has 
been identified5. This trend was found particularly in gastric22, colon23, colorectal24, 
cervical25, breast26, lung13, ovarian27, pancreatic28 and prostate cancers29. This 
discovery has lead to the suggestion that the expression level of 67kDa laminin 
receptors could be a reliable method of prognosis for metastatic tumors28,29. 
Furthermore the over-expression of this receptor could provide an opportunity for 
cancer therapy directed at this site.  
  
Human fibrosarcoma (HT-1080) cells that were pretreated with an anti-LRP antibody 
showed significantly reduced lung metastasis compared to untreated cells in a murine 
model30. In vivo studies demonstrated that suppression of LRP expression lead to a 
reduction in the proliferation and tumor formation of lung cancer cells31. Furthermore, 
the application of an anti-LRP/LR antibody (P4G) proved to have a significant 
regulatory effect and reduced lung metastasis in murine models32.   
 
Most forms of prion disease therapy directed at LRP/LR have the potential to be 
utilized in tumor intervening therapy. A study done using HT1080 cells have 
illustrated that the blocking or down-regulation of the LRP/LR receptor minimized 
the invasive potential of these cells33. Interference of the laminin-LRP interaction 
results in a significantly hindered invasion. Ways in which this can be achieved 
include anti-LRP/LR antibodies, such as full-length format (scFv) IgG1-iS18, as well 
as heparan mimetics and pentosan polysulfate33. The success of this brings forward 
the possibility of developing alternative methods capable of reducing the metastatic 
nature of cancer.  Interestingly, a recent study has shown a definite link between 
LRP/LR and the maintenance of cell viability5. An increased level of LRP/LR found 
  7 
on the neoplastic cell line HT-108033 in conjunction with the fact that LRP/LR 
inhibits apoptotic processes5 indicates that the receptor plays a critical role in the 
progression of cancer and the development of metastatic tumors.      
 
As mentioned previously, the LRP/LR plays a key role in tumorigenic processes 
including cell adhesion, angiogenesis34 and cell migration35. Not only has the 67kDa 
high affinity laminin receptor found to be over-expressed in lung and breast 
carcinomas36, auto-antibodies have been found in the blood of breast cancer patients 
directed against the 37kDa LRP37. A direct correlation between the 37kDa/67kDa 
LRP/LR level and the metastatic as well as invasive potential has also been 
observed36.  
 
The process of metastasis is complex and can be summarized as the following steps: 
breaking off from primary tumor, movement through blood vessels and finally the 
formation of a secondary tumor at a new location (Figure 4). Cell invasion is a critical 
event in the formation of metastasis and is mediated through attachment and 
degradation of Extracellular Matrix (ECM) components such as proteoglycans, 
collagens and laminins. This degradation is achieved with the use of various enzymes 
such as serine, threonine proteases and Matrix Metalloproteinases (MMP). The 
interaction between Laminin-1 and the 67kDa LR enhances the ability of tumorigenic 
cells to invade tissue due to the activation of these proteolytic enzymes38. These 
extracellular proteases, such as type IV-collagenase, which is an MMP, are able to 
degrade Laminin-1 as well as collagen type IV and lead to promotion of primary 
tumor cell migration through the ECM39(Figure 5 & 6).  Once the tumorigenic cell 
has traversed the basement membrane it is able to enter nearby vessels such as blood 
vessels and lymph. Once inside the vessel these cells may not survive due to the 
changes in the environment, as some are only able to remain viable if attached. Some 
tumorigenic cells may be recognized and neutralized by cells of the immune system, 
such as natural killer cells and natural killer T cells, which are the body’s innate 
defense against metastasis. How and where the migrating cells stop is different for the 
various cancer types and once the tumorigenic cells are no longer moving, they can 
begin the process of forming a new tumor by leaving the blood vessel40. It then 
proliferates and a secondary tumor is formed due to the metastasis of the primary 
tumor cells.  
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Figure 4: Illustration of the process of tumor metastasis. 1. Cells from original tumor attach to 
basement membrane of blood vessel and interact with the Laminin Receptor (LR). The basal 
lamina is then digested by MMP2/9 allowing for tumor cell entry into blood stream and 2. 
Migration. 3. A metastatic  (secondary) tumor is then established by attachment of migrating 
cells to the blood vessel and movement into distal tissue41. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Electron micrograph showing HT1080 cells having digested Matrigel™ matrix 
migrating through 8µm pore of the membrane. 
(http://www.ebiotrade.com/buyf/productsf/BD%20Biocoat/354481.htm, Retrieved January 6, 
2012).  
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Figure 6: Schematic diagram illustrating cell invasion involving LRP/LR by cell adhesion, 
and MMP2/9 ECM degradation allowing for cell migration.  1.) Attachment of tumorigenic 
cell to Laminin-1 on the basement membrane via the Laminin Receptor, 2.) Digestion of the 
basal lamina by type IV collagenase secretion induced upon attachment, 3.) Degradation of 
the basement membrane allows for tumorigenic cell motility into the blood stream.  
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1.7 Antibodies   
In order to neutralize antigens invading the body, immunoglobulins (Igs) also known 
as antibodies are synthesized. In most cases antigens are proteins, polysaccharides or 
nucleic acids originating from bacteria, viruses or other microorganisms. 
Immunoglobulins are full-length antibodies consisting of a heavy chain (HC) and a 
light (LC) chain (Figure 7). The former is built up of an antigen-binding variable 
domain and a constant domain.  The latter, contains an N-terminal variable domain as 
well as a C-terminal domain that is constant. The variable domains are 
interchangeable between antibodies allowing for the binding of many different 
antigens.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Illustration of a full-length immunoglobulin with its structural domains, showing the 
antigen binding sites as well as indicating (in red) the light chain and the heavy chain (in 
blue).  
 
Currently, there are several ways of producing antibodies, however, very few are 
capable of producing monoclonal antibodies (MAb’s) rather than polyclonal ones. 
Injecting rabbits with the appropriate antigen easily produces polyclonal antibodies. 
The serum from the rabbits’ blood will then contain the antibodies against this 
antigen, as well as a host of other antibodies. The challenge at this stage is then 
isolating the required antibodies from this heterogenic solution, since in most cases it 
would prove to be ineffective as a therapeutic treatment. A polyclonal serum only 
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consists of 5-10% of the antibody directed against the antigen used for 
immunization42. Another disadvantage is that the amount of a polyclonal antibody 
that can be produced is limited. It is for these reasons that a technique was developed 
to produce a single class of antibodies in a serum (i.e. MAb’s). The hybridoma 
technique involves the fusion of a short-living antibody producing cell with an 
immortal myeloma cell, resulting in the production of a single type of antibody43. This 
technique has opened up several windows of opportunity in the production of 
therapeutic antibodies. The development of monoclonal antibodies has offered new 
perspectives in therapeutic treatments. The over-expression of monoclonal antibodies 
in Escherichia coli has been successfully demonstrated44.  
 
1.8 Therapeutic antibodies  
Monoclonal antibodies can be utilized as a therapeutic agent for the treatment of 
various diseases including cancer (Table 2). This is possible due to their ability to 
specifically bind to target cells or proteins and flag them for the destruction by the 
immune system (e.g. Herceptin)45.  The mode of action of these antibodies can vary, 
and includes blocking specific receptors linked to tumor growth thereby hindering 
proliferation and progression. In other instances, such as in radio-immunotherapy a 
radioactive dose is localized on targeted cancer cells46. Antibody-drug conjugates 
(ADC’s) are a revolutionary new form of therapeutic antibodies that are designed to 
combine monoclonal antibodies and their anti-cancer activities with potent 
cytotoxics47. These antibodies are able to selectively neutralize cancer cells while 
minimizing effects on normal tissue.  
 
MAb’s present a promising tool in metastatic cancer treatment and have been found to 
illicit appropriate immune responses in murine models30. The efficacy of these MAb’s 
is highly dependant on their structures and consequently their half-lives, which can 
range from approximately 12 hours for single chain antibodies to 2-3 weeks for full-
length antibodies42. A longer half-life is imperative for in vivo studies therefore, 
making full-length antibodies more suitable. Mammalian and bacterial cells differ as 
expression systems in terms of their expression level, growth speed and post-
translational modifications. The expression of functional full-length immunoglobulins 
is not possible in E. coli since the bacterial translation machinery cannot perform 
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glycosylation and form sulfide bridges. It is for this reason that mammalian cells are 
used since protein synthesis in these cells results in the formation of the disulfide 
bonds, and correct folding within the Endoplasmatic Reticulum (ER). However, the 
antibodies must be secreted into the extracellular space to avoid exposure to the 
reducing environment inside the cells and this then warrants the formation of the 
disulfide bridges. The production of effective IgG’s is made possible by co-
transfecting the mammalian cells (HEK 293 EBNA) with plasmids encoding for the 
heavy and light chain.  
 
Table 2: Currently available monoclonal antibodies for the treatment of cancer46 
Antibody Trade 
name 
Approval 
date 
Type  Target  Indication  
Bevacizumab Avastin 2004 Humanized  Vascular 
Endothelial 
Growth 
Factor 
(VEGF) 
Colorectal 
cancer, lung 
cancer  
Cetuximab Erbitux 2004 Chimeric Epidermal 
growth 
factor 
receptor 
Colorectal 
cancer, 
head and 
neck cancer  
Ipilimumab 
(MDX-101) 
Yervoy 2011 Human Blocks 
CTLA-4 
Melanoma  
Panitumumab Vectibix 2006 Human  Epidermal 
growth 
factor 
receptor 
Colorectal 
cancer  
Trastuzumab Herceptin  1998 Humanized  ErbB2 Breast 
cancer 
Edrecolomab Panorex 1995 Murine  EpCAM Colorectal 
cancer  
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1.9 Anti-LRP/LR specific antibody IgG1-iS18   
Since it has been found to be involved in several cancer-associated processes, 
LRP/LR would then serve as an obvious target in the treatment of metastatic cancer32. 
Studies have also shown the effective treatment of Prion diseases with the application 
of therapeutic antibodies that target LRP/LR42,48,49. The efficacy of this approach 
could be assessed by blocking the invasion of tumorigenic human fibrosarcoma HT-
1080 cells by several anti-LRP/LR antibodies as well as anti-LRP/LR tools including 
siRNA and heparan mimetics33. siRNA’s are small interfering RNA’s and form a 
class of double-stranded RNA molecules that interfere with the expression of specific 
genes, while heparan mimetics act as competitors of endogenous heparan sulphates 
known to act as co-receptors in the process of metastasis.  Anti-LRP/LR tools that 
have successfully impeded the invasive nature of HT1080 cells include the single-
chain scFv iS18, the full-length IgG1-iS18 antibodies, the polysulfated glycans 
HM2602 and pentosan polysulfate (SP-54)33. It was found that the epitope for IgG1-
iS18 antibody stretches from amino acid (aa) 272-280 of LRP: TEDWSAAPT33. This 
site is located close to the C-terminus end, which is exposed to the extracellular space, 
however it is not located in the direct laminin-binding site50. An indirect binding 
created by heparan sulfate proteoglycans is thought to be located in the 180-285aa 
region of LRP.                      
  14 
    
1. 10 Aims and objectives   
 
Aim: 
The aim of this study was to prove that the LRP/LR specific antibody (IgG1-iS18) 
significantly reduces the metastatic potential of important cancer types in South 
Africa. 
 
Main objectives: 
1. Determination of the surface level of LRP/LR by Fluorescent Activated Cell 
Scanning (FACS) on the following neoplastic cell lines HT-1080 (human 
fibrosarcoma cells), A-549 (human lung carcinoma cells), HeLa (human 
cervix carcinoma cells), MCF-7 (human breast carcinoma cells), SW-480 
(human colon adenocarcinoma) and LNCaP (human prostate carcinoma).  
2. Investigation of the invasive potential of the tumorigenic cells lines mentioned 
in 1 by performing invasion assays. 
3. Investigation of a significant inhibitory effect of the anti-LRP/LR specific 
antibody IgG1-iS18 (IgG1-HD37 anti-CD19 for control) on invasion and 
adhesion of the tumorigenic cell lines mentioned in 1.                   
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CHAPTER TWO – MATERIALS  
 
2.1. Molecular biology   
2.1.1 Plasmids   
The following vectors encoding for the heavy and light chains of the full-length IgG1-
iS18 anti-LRP/LR antibody and the full length IgG1-HD37 anti-CD19 were used: 
• IgG1-iS18 
- pEU1.2VH_S18 (heavy chain)  
- pEU4.2VL_S18 5-4-1 (light chain) 
 
• IgG1-HD37 
- pEU1.2VH/Fcg1 (heavy chain)  
- pEU1.2VL/Ckappa (light chain)  
 
These plasmids were used to co-transfect HEK 293 EBNA cells to produce full-length 
antibodies.  
 
 
2.1.2 Bacterial strains  
 
Table 3: E. coli strain XL1Blu was used for the over-expression of the IgG encoding 
vectors 
 
Media composition 
Luria Bertani (LB) medium 1% (w/v) Bacto-Trypton;  
0.5% (w/v) Bacto-Yeast; 
0.5% (w/v) NaCl 
 
Luria Bertani (LB) Ampicillin 
medium  
100µg/ml Ampicillin in LB medium 
 
      
  16 
    
2.2 Cell culture  
2.2.1 Eukaryotic cell lines   
Table 4: Cell lines for in vitro experiments  
Cell line  Cell type  
Neoplastic  
HT-1080 Human fibrosarcoma (positive control) 
A549 Human lung carcinoma  
HeLa Human cervix carcinoma 
SW480 Human colon adenocarcinoma  
LNCaP Human prostate carcinoma 
Negative control  
MCF-7 Human breast adenocarcinoma 
NIH/3T3 Control mouse embryonic fibroblasts 
Antibody production  
HEK293 EBNA 
 
Human embryonic kidney cells expressing 
Epstein Barr Virus nuclear antigen 
2.2.2 Cell culture media   
The main cell lines require different media prepared from the following components:  
• Dulbecco´s modified Eagle Medium (DMEM high glucose) (1x), with 
GlutaMAX ™ l, 4.500mg/L D-Glucose (HT-1080, A549, HeLa and MCF-7, 
NIH/3T3).  
• RPMI 1640 (SW480 and LNCaP) 
All the above culture media was supplemented with: 
• 10% fetal calf serum (FCS) heat inactivated.  
• 1% Penicillin-Streptomycin. 
 
Additional supplements for cell culture:  
• Dulbecco´s Phosphate-Buffered Saline (D-PBS) (1x) liquid. 
• Trypsin/EDTA (1x). 
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Table 5: Storage of main cell lines needs special freezing media made up of the following 
Cell line Composition of specific freezing media  
HT-1080 70% medium, 20% FCS, 10% DMSO, 1-2 x 106 
cells/ vial 
A549 70% medium, 20% FCS, 10% DMSO, 1-2 x 106 
cells/ vial  
HeLa 70% medium, 20% FCS, 10% DMSO, 1-2 x 106 
cells/ vial 
SW480 70% medium, 20% FCS, 10% DMSO, 1-2 x 106 
cells/ vial 
LNCaP 70% medium, 20% FCS,  10% DMSO, 2 x 106 cells/ 
vial 
MCF-7 70% medium, 20% FCS, 10% DMSO, 1-2 x 106 
cells/ vial 
NIH/3T3 70% medium, 20% FCS, 10% DMSO, 1-2 x 106 
cells/ vial 
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2.2.3 Cell culture material   
To culture the eukaryotic cells the following material was required:  
• Tissue culture (TC) flasks 75 cm² and 150 cm²  
• Serological pipettes sterile (5 ml, 10 ml, 25 ml)  
• Centrifugation tubes (15 ml, 50 ml)  
• TC-Plates 24 well, 96 well  
• Transwell culture plate inserts, millipore Ø 8µm  
• Tissue culture dishes (Ø 150 x 20 mm)  
• Transwell culture plate inserts, millipore Ø 8µm  
• CryoTube™Vials  
2.2.4 Material for cell lysates   
• Lysis buffer:       
- 10 mM Tris/HCl pH 7.5  
- 100 mM NaCl  
- 10 mM EDTA  
- 0.5% (v/v) Nonidet-P40  
- 0.05% (w/v) Deoxycholic acid (DOC)  
- Stored at 4-8°C  
2.2.5 Material for transient transfection  
• Cells:     HEK293 EBNA  
 
• Plasmids:   - pEU1.2VH_S18 (heavy chain)  
           - pEU4.2VL_S18 5-4-1 (light chain) 
           - pEU1.2VH/Fcg1 (heavy chain)  
                            - pEU1.2VL/Ckappa (light chain)  
 
• 2xHEBS buffer: 280 mM NaCl; 1.5 mM Na2HPO4; 50 mM HEPES; pH 7.05  
• 250 mM CaCl2    
• Media:       - DMEM high glucose, 10% FCS 1% P/S  
            - DMEM high glucose, 1% P/S, 1% Insulin-Transferrin-Selenium 
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2.2.6 Material for invasion and adhesion assays   
• Cells:   HT-1080, HeLa, A549, MCF-7, SW480, LNCaP  
 
• Antibodies:   IgG1-iS18, IgG1-HD37 
 
• Media:              1%, 10% FCS and serum-free variants of the                                    
corresponding cell media  
 
• 96-well plate 
• 1% SDS Solution   
• 1x PBS Solution     
• 0.5% Toluidine Blue   
• 0.5% Trypan Blue  
• Neubauer haemocytometer  
• Matrigel™   
• Media containing agar 
• Laminin-1  
• Blocking solution  
• 0.1% Crystal Violet 
• 3.7% Formaldehyde 
• 33% Acetic acid 
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2.3 Protein biochemistry  
2.3.1. Solutions and reagents  
Table 6:  Solutions used in SDS-PAGE  
SDS-PAGE 
Ammonium peroxisulphate 
(APS) 
10% in ddH2O 
Upper Tris Buffer 0.5 M Tris, pH 6.8 4g/L SDS  
 
Lower Tris Buffer 3 M Tris, pH 8.8 4g/L SDS  
 
10x SDS running buffer 250 mM Tris, 1.92 mM Glycine in ddH2O and 10% 
SDS 
1x SDS running buffer  1% 10x SDS running buffer  
 
5x SDS loading buffer 30% Glycerine, 312 mM Tris/HCl pH 6.8, 10% SDS  
 
Coomassie staining  
 
1.5 g/l Coomassie Brilliant Blue R250, 10% acetic 
acid, 30% ethanol in ddH2O  
Destaining solution  10% acetic acid, 30% ethanol in ddH2O  
Table 7:  Solutions used in Western Blotting  
Western Blotting 
10x PBS 80 g NaCl, 2.0 g KCl, 14.4 g Na2HPO4 x 2H2O, 2.4 g 
KH2PO4, ddH2O pH 7.4  
1x PBS Tween 1% 10x PBS, 0.1% TWEEN 20 in ddH2O 
1x Transfer Buffer 20% methanol in 25 mM Tris and 19.2 mM Glycine 
Blocking Buffer 3% Non-fat milk in 1x PBS-Tween  
Washing Buffer 1x PBS-Tween 
Stripping solution 1% SDS, 1mM Glycine, 0.1% Nonidet-P40, pH 2.2  
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Table 8: Solutions used in IgG purification  
2.3.2. Antibodies  
Table 9: Different antibodies were used in the various analyses 
Note: All dilutions were done in 10% horse serum in 1x PBS-T or 5% milk powder in 
0.2% 1xPBS-T(1% 10x PBS, 0.2% TWEEN 20 in ddH2O)  
IgG purification 
Steritop filter blocking solution  150 ml 2% BSA in ddH2O  
Wash/Binding buffer  DMEM high glucose with GlutaMAX™ l, 4.500 
mg/L D-Glucose, pH 7 
Elution buffer  0.1M Glycine HCl pH2.7, 140mM NaCl 
IgG storage buffer 1M Tris/HCl pH 8.8  
Column storage solution 20% ethanol  
Dialysis buffer 1x PBS  
Western Blotting 
Detection of LRP/LR 
Primary Antibody  IgG1-iS18 (1:10000) 
Secondary Antibody Goat-anti-human-POD (1:5000) 
Tertiary Antibody Anti-rabbit  
Detection of ß-Actin 
Primary Antibody Mouse-anti- ß-Actin (1:5000) 
Secondary Antibody Rabbit-anti-mouse IgG1-POD (1:5000) 
Fluorescence activated cell scanning (FACS) 
Detection of LRP/LR 
Primary Antibody  IgG1-iS18 (1:100) 
Secondary Antibody Rabbit polyclonal to human IgG-H&L (FITC coupled)(1:100) 
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CHAPTER THREE – METHODS  
3.1. Molecular biology  
3.1.1 Plasmid DNA isolation   
Plasmid isolation was done using a Plasmid Mega and Maxi Prep Kit according to the 
manufacturers protocol (Qiagen, Invitrogen). It is based on the alkaline lysis 
procedure whereby chromosomal and plasmid DNA are denatured, however selected 
plasmid DNA is re-natured under neutralization. This was then purified by anion 
exchange chromatography and isopropanol precipitation. After washing with 70% 
ethanol it was then air-dried and dissolved in TE-buffer. Plasmid DNA was quantified 
by NanoDrop® ND-1000. This is a full-spectrum (220-750nm) spectrophotometer 
that was used to measure small samples (~2µl) with high accuracy.  It is able to 
analyze sample absorption and determine the concentration.  
3.2. Cell culture  
3.2.1 Cell cultivation   
The various cell lines were cultivated in the appropriate medium at 37°C in a 
humidified 5% CO2 atmosphere (Incubator from Heraeus), using tissue culture dishes 
(Ø 150 x 20 mm). Following the removal of media, confluent cells were washed with 
5 ml PBS and detached with 1 ml of Trypsin/EDTA. Cell detachment was stopped by 
addition of 8.5 ml of media containing 10% FCS and detached cells were passaged in 
dilutions ranging from 1:2 to 1:25 in order to maintain optimal growth.  
 
3.2.2 Freezing and thawing of cells   
Freezing of cells:  
The various cell lines were frozen for safekeeping. Confluent cells were detached and 
centrifuged at 1200rpm for 10 minutes. The resulting pellet was then re-suspended in 
freezing media. Aliquots (1ml) of the suspension were then frozen for 24 hours at -
20°C and finally stored at -80°C until needed. 
Thawing of cells:  
Frozen cells were removed from a -80°C freezer and thawed on ice. Thawed cells 
were transferred to the appropriate media containing 1% Penicillin/Streptomycin and 
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20% FCS. This was then centrifuged at 1200rpm for 5 minutes and the pellet re-
suspended in the same media used previously. Cell suspension was transferred to a 
cell culture dish and incubated at 37°C, 5% CO2. The growth of the cells was 
monitored over the next 5 hours and the media changed to 10% FCS upon cell 
attachment.   
 3.2.3 Cell count determination   
In order to maintain a constant number of cells during experiments with the various 
cell lines, a cell count was performed. This involves Trypan-blue staining where 
viable cells appear clear and dead cells stain blue. These cells can then be counted 
using a Neubauer haemocytometer. Briefly, cells were washed with DPBS, detached 
with Trypsin/EDTA and suspended in the appropriate media. An aliquot of the cell 
suspension was mixed with the equivalent amount of Trypan-blue solution (0.4 %). 
10 µl was placed on the haemocytometer and the mean cell average in 16 small 
squares counted under the light microscope. The cell number was then calculated 
according to following formula:  
Mean average of cells in 16 small squares x 104 = number of cells/ml. 
       4 
3.2.4 Preparation of cell lysates   
Cells were washed with DPBS and detached in the same manner mentioned 
previously. The suspension was then centrifuged for 10 minutes at 1200rpm and the 
pellet re-suspended in 500 µl of lysis buffer. Following 15 minutes incubation on ice, 
lysates were centrifuged at 14000 rpm for 2 minutes.  
3.2.5 BCA™ protein assay   
The BCA™ Protein Assay is a method used to quantify the total level of protein in a 
solution by colorimetric analysis. It is based on the reduction of Cu2+ to Cu+ by the 
peptide bonds found in proteins, and the formation of a violet complex of Cu+ with 
bicinchoninic acid (BCA, 2,2´-Bichinolin-4,4´-dicarbonicacid). The amount of Cu2+ 
that is reduced is an indication of the protein concentration present in the sample. 
Following an incubation at room temperature, the absorbance was measured at 562nm 
using an ELISA reader.  
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3.3 Antibody production  
3.3.1 Synthesis of IgG1-iS18 and IgG1-HD37 in mammalian cells   
Human embryonic kidney 293 (HEK 293 EBNA) cells stably transfected with the 
Epstein-Barr virus EBNA 1 gene were transiently transfected with the plasmids 
encoding for the IgG1 antibodies. The EBV EBNA 1 protein has been shown to give 
a significantly higher expression level if a vector (such as the IgG1-iS18 encoding 
vector) contains oriP of EBV and would therefore result in a high yield expression.  
Calcium phosphate precipitation was used for the transfection of the mammalian 
cells.  Calcium phosphate is precipitated from a HEPES-buffered saline solution 
(2xHEPES) containing phosphate ions and a Calcium chloride solution. The DNA to 
be transfected then binds to this precipitate and thereafter is taken up by the target 
cells via endocytosis. After it is released into the cytoplasm of the cell, the DNA is 
transported into the nucleus to be transcribed. Cultured HEK 293 EBNA cells were 
transfected with the plasmid encoding for the heavy and light chains. Following an 
incubation time of 16 hours with the plasmid, the mammalian cells were washed with 
DPBS and re-suspended in pre-warmed media containing ITS (Insulin-Transferrin-
Selenium). After 24 hours the supernatant containing the secreted antibodies was 
collected and the cells re-suspended in ITS supplemented media for a further 24 
hours. The supernatant was then centrifuged for 10 minutes at 1200rpm to remove 
debris and stored at -80°C until it was purified. 
 
3.3.2 Purification of IgG1-iS18 and –HD37 by protein A sepharose affinity 
chromatography   
Affinity chromatography was employed as the method of purifying the solution 
containing the antibodies that were produced by the HEK 293 EBNA cells. The 
process is based on the principle of antigen-antibody binding between an 
immobilization phase and the proteins of interest. Protein A Sepharose™ contains 
receptor molecules derived from the bacteria Staphylococcus aureus. These molecules 
provide four high affinity (KA 106/M) binding sites that are able to bind to the Fc 
regions of immunoglobulins (IgG) of many mammalian species through heavy chain 
interactions.  
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The purification involves multi-step chromatography and immobilized by generating 
a stable thioether linkage to Sepharose 4 Fast Flow. This highly cross linked, 4% 
agarose derivate base matrix and the high affinity binding of Protein A allow for rapid 
processing of large volumes of dilute cell culture fluid, and was therefore the most 
appropriate method for the purification of the antibodies.  
 
3.3.3 Dialysis of IgG1-iS18 and IgG1-HD37  
Dialysis is a term frequently mentioned in the literature as a technique to remove salt 
or other small molecules and to exchange buffer composition of a sample. Since the 
molecular weight of IgG is 150kDa and the molecular weight of the unwanted salts 
are 100-5000Da, the membrane used in the dialysis had a Molecular Weight Cut Off 
(MWCO) of 2000-5000Da. The cellulose membrane consists of cross-linked cellulose 
fibres making the pores irregular gaps of varying form and size instead of defined 
holes. Since the permeability of the membrane also depends on other factors such as 
the molecular shape, globular molecules are retained more efficiently than fibrillar 
molecules. Therefore, dialysis cannot perform strict separation of molecules, but 
simply an accumulation of big molecules inside the tube and sufficient removal of 
unwanted molecules such as salts. This is done in a beaker filled with dialysis buffer 
(1% PBS) on a magnetic stirrer at 4°C for 18 hours. The dialysis buffer was changed 
twice during this period. Following dialysis the membranes were rinsed with sterile 
distilled water and the antibody stored at -20°C. All materials during this procedure 
were sterilized and the resulting preparation was handled aseptically. 
3.3.4 Detection of IgG1-iS18 and IgG1-HD37  
Detection of the antibody produced was done using SDS-PAGE and subsequent 
overnight staining of the gel with Coomassie Blue. De-staining was then performed 
by cooking the gel in water for 3 x 5 minute periods in the microwave. Gel-doc 
imaging was used to record the bands present.  
3.3.5 Quantification of IgG1-iS18 and IgG1-HD37  
The antibody present in the solution consequent to the dialysis was quantified using a 
Nano-drop (280nm) with the storage buffer serving as the blank.   
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3.4 FACS (Fluorescence activated cell scanning)    
Fluorescence activated cell sorting/scanning is a method employed to determine the 
expression level of proteins or to separate cells according to their surface protein 
expression. This method was used to determine the cell surface levels of LRP/LR on 
tumorigenic cell lines. The protein of interest was detected with an antibody, and a 
fluorescence dye (e.g. FITC) labeled secondary antibody directed against the primary 
antibody. A blue argon laser in a flow cytometer distinguished the labeled from the 
unlabeled cells from the fluorescence emitted by the FITC. FITC has excitation and 
emission spectrum peak wavelengths of approximately 495nm/521nm and the 
fluorescence detected by the FL1 channel. Samples were tested with both the IgG1-
iS18 and IgG1-HD37 antibodies and with the FITC labeled antibody only in order to 
detect possible background emission. Confluent cells were detached and centrifuged 
for 10 min at 1200 rpm, with the resultant pellet re-suspended in 1 ml 4% PFA and 
incubated for 10 minutes at 4°C in order to fix them. This step was then followed by 
another centrifugation of 10 min at 4000 rpm, and the pellet re-suspended in 1ml 
FACS-buffer. At this point the cell suspension was then separated into 2 even halves 
and centrifuged in the same manner. One of the pellets was re-suspended in 100 ml of 
the primary anti-LRP/LR antibody IgG1-iS18 (c=30mg/ml), while to the other one 
with 100 ml of FACS-buffer only (incubation time of 2 hours). After 3 washing steps, 
100 µl of secondary anti-human-FITC antibody (c=20mg/ml) was added to both 
samples and once again incubated for 2 hours. The samples containing the secondary 
antibody only, acted as a control for background emission. After washing the samples 
another 3 times, the cells were finally re-suspended in 1ml of FACS-buffer and 10 
000 cells measured by FACS (Beckmann COULTER EPICS® XL-MCL).  
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 3.5 Invasion assays  
The experimental approach to determine the potential of cells to invade an 
extracellular matrix (ECM) is the chemo-invasion assay. It makes use of a chemo-
attractant on the lower site of a polycarbonate filter to introduce cell invasion through 
an ECM-like Matrigel™ and the pores of a filter membrane by chemotaxis (Figure 8). 
The pore size has to be big enough for the cells to move through but must be small 
enough for them not to fall through. For eukaryotic cells the optimal pore size is at 
approximately 8µm. The attractant can vary but in this case 10% FCS was used. The 
period of incubation time is a major factor for the success of the assay, since 
incubation for too long would lead to migration into the reservoir and would distort 
the result, while a short incubation would lead to insignificant results. Due to this and 
the different invasive potentials, incubation time has to be adjusted and optimized. 
The Matrigel™, which was used, mimicked the basement membrane with its major 
components being laminin, collagen IV, and heparan sulfate proteoglycans. 
              
Figure 8: Principle of invasion assay – cells invading transwell insert with membrane (8µm 
pore size) and Matrigel™. This system serves as a model to mimic the interaction with the 
basement membrane. Cells with invasive potential are able to move through the pores and the 
Matrigel™ as they are drawn toward the chemo-attractant (10% FCS). Note, in the diagram 
FBS represents FCS.  
(http://www.cellbiolabs.com/sites/default/files/CBA-110%20Fig%201.jpg)   
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3.5.1 Preparation of Transwell inserts, cells and determination of invasive potential  
Matrigel™ was diluted to 1mg/ml in serum-free cell culture media. 100µl of the 
diluted Matrigel™ was transferred to the upper chamber of a 24-well transwell plate. 
This was then incubated at 37°C for 6 hours, during which time it formed a gel. The 
harvested cells were then washed with culture media (1% FCS) and re-suspended in 
this same media at a concentration of 1x106 cells/ml. It is at this point that cells are 
incubated with the IgG1-iS18 antibody or the control IgG1-HD37 antibody for 10 
minutes. 100µl of the cell suspension was loaded on to the gel while the lower 
chamber was filled with 500µl of serum-free culture media for the control and 500µl 
of culture media containing 10% FCS for the rest. This was then incubated at 37°C 
for 18hours. Samples were taken at certain time intervals in order to ascertain the 
ideal incubation time. Thereafter the upper and lower media were removed and the 
cells fixed with 300µl of 4% Paraformaldehyde (PFA), rinsed with 300µl DPBS and 
subsequently stained with 100µl of 0.5% Toluidine blue. Non-invading cells were 
then scraped off with a cotton swab and the dye on the invasive cells extracted with 
300µl 1% SDS. The resulting solutions were then transferred to a 96 well microtiter 
plate and the absorbance was determined at 620nm in an ELISA reader. Experiments 
were performed in triplicate. As mentioned, cells placed in reservoirs containing 
serum-free media acted as negative controls in conjunction with cells incubated with 
the IgG1-HD37 control antibody.  
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3.6 Adhesion assay  
To determine the ability of certain cell lines to adhere to a specific adhesive substrate, 
the adhesion assay was performed in 96-well plates coated with Laminin-1. To 
evaluate the efficacy of the anti-LRP/LR antibody, the cells were pre-incubated for 10 
minutes with IgG1-iS18 and IgG1-HD37 (as a negative control). The surface of a 96-
well plate was incubated with blocking solution  (1% FCS in PBS). Cells suspended 
in serum-free media were added to the wells and incubated for 1 hour. After 1-hour 
incubation the attached cells were thoroughly washed with PBS, fixed in 3.7% PFA 
and then stained with 0.1% crystal violet. The pigment was extracted with 1% SDS 
and the absorbance was measured at 570 nm. This absorbance acted as an indicator of 
cells attached to Laminin-1 (Figure 9).  
Figure 9: Illustration of the adhesion assay where wells are coated with Laminin-1 and cells 
are then incubated in these wells, attached cells are then stained and this absorbance 
measured. The amount of dye extracted being a representation of the number of cells that had 
attached.  
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3.7 Protein Biochemistry 
3.7.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)   
In order to visualize the relative protein expression and total LRP/LR levels in 
tumorigenic cell lines an SDS-PAGE was performed. This technique is able to 
separate proteins according to their electrophoretic mobility. These proteins are heat 
denatured in the presence of the detergent sodium dodecyl sulfate (SDS) and the 
reducing agents dithiothreitol (DTT) or ß-mercaptoethanol. The manner in which SDS 
denatures the proteins is by firstly disrupting non-covalent bonds resulting in the loss 
of their native conformation. A negative charge then forms on the protein due to the 
binding of anions. However, due to the proteins native charge an electrostatic 
repulsion occurs resulting in the unfolding of the protein. Following the addition of 
SDS proteins become negatively charged overall. In the consequent separation by 
electrophoresis, a polyacrylamide gel acts as a sieve in which smaller proteins are 
able to travel further. Therefore, the mobility (linear function of the logarithm) of a 
protein shall serve as an indication of its molecular weight. The pore size of a gel can 
be altered by adjusting the amount of acrylamide, and cross-linkage with 
polymerization following the addition of APS (Ammonium persulfate) and TEMED 
(N, N, N', N'-tetramethylethylenediamine). In this study it was necessary to separate 
proteins in the range of 10-100kDa in size. For this, 12% polyacrylamide gels were 
used. Protein markers were loaded on each gel and served as a reference for protein 
sample sizes.  
 
3.7.2 Western Blotting    
Western Blotting is an analytical technique used to detect specific proteins. This is 
achieved by firstly separating the proteins using gel electrophoresis (e.g. SDS-PAGE) 
and the resultant proteins are then electro-transferred to a membrane (e.g. PVDF, 
Nitrocellulose). This membrane is then probed using antibodies that contain binding 
sites specific for the protein you wish to detect. Finally, the secondary peroxidase-
coupled (POD) antibody, catalyses light emission from the oxidation of luminol at 
428 nm and the light emission from the resulting reaction and is then captured on x-
ray film.  
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Cell lysates were prepared following the method mentioned previously and the 
BCA™ protein assay (please refer to 3.2.5.) was then employed to quantify the total 
protein levels and standardized the amount of protein that was loaded on to the SDS-
polyacrylamide gel. The protein transfer was performed electrophoretically on PVDF 
(Biotrace™ PVDF Blotting membrane, 0.45µm pore size, Pall Corporation) in a 
PerfectBlue™ Semi-Dry Electroblotter (Peqlab) chamber according to the 
manufacturer’s instructions. The PVDF membrane was first equilibrated in methanol 
and then placed in transfer buffer, and filter paper which was soaked in transfer buffer 
prior to transfer. The blotting procedure was carried out at 350mA for 45 minutes 
(Figure 10).  
 
 
 
 
 
 
 
 
Figure 10: Principle of the semi-dry Transfer Western Blotting method 
3.7.3 Protein detection and chemiluminescence   
Due to the proteins being bound to the membrane, non-specific binding sites were 
blocked with blocking buffer for 1 hour. The membrane was then incubated in the 
primary antibody solution for 1 hour at room temperature. Subsequent to this, the 
membrane was washed then incubated with the appropriate secondary antibody for 1 
hour at room temperature and detection done immediately after 3 x 10-minute washes. 
The secondary antibody used in the Western Blotting procedure is coupled with a 
peroxidase. Peroxidases, such as the horseradish peroxidase, catalyze the oxidation of 
luminol resulting in the emission of light (Figure 11). Antibodies labeled with 
horseradish peroxidase are able to react directly with immobilized protein antigens. 
For detection of the target proteins in this study SuperSignal WestPico 
Chemiluminescent Substrate was employed. Following the addition of 1ml of stable 
peroxide solution and 1ml of luminol/enhancer solution, fluorescence was visible and 
captured on x-ray film that was then developed.  
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Figure 11: Immuno-detection of proteins showing the protein bound to the membrane, the 
primary antibody (1°Ab) attached to this, and the secondary antibody (2°Ab) attached to the 
1°Ab. The figure also shows the Horse-Radish Peroxidase (HRP) and the oxidation of 
luminol resulting in light emission.    
3.8 Data analysis and statistical evaluation   
Statistical analyses were performed using a two-tailed Student’s t-test with a 95% 
confidence interval. p-Values of less than 0.05 were considered significant.  
* p < 0.05, ** p < 0.01, *** p < 0.001.  The linear dependence between two variables 
was expressed using Pearson’s (r) correlation coefficient.         
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CHAPTER FOUR – RESULTS  
4.1 Production of anti-LRP/LR specific antibody IgG1-iS18 in mammalian cells   
The synthesis of antibodies in most cases is achieved by employing two vector DNA 
molecules, one that carries the light-chain gene and the other that carries the heavy-
chain gene. However, this approach could result in an imbalance of the biosynthesis 
of two polypeptides, i.e. the heavy and light chains. It is for this reason that careful 
consideration and calculation of the HC:LC is done in order to utilize the optimal 
ratio for IgG1 assembly in the ER51.    
4.1.1 Characterization of the plasmids   
Plasmid DNA was prepared from pEU1.2VH_S18 encoding for the heavy chain of 
the antibody IgG1-iS18 and pEU4.2VL_S1 5-4-1 which encodes for the light chain of 
the anti-LRP/LR specific antibody IgG1-iS1833. pEU1.2VH/Fcγ1 encoding for the 
heavy chain of IgG1-HD37 and pEU1.2VL/Cκ encoding for the light chain of IgG1-
HD3733. The IgG1-HD37 served as the control antibody directed against CD19 on the 
surface of human B cells.  These vectors were amplified in E. coli and the DNA 
extracted and purified using the GenElute HP Plasmid maxi preparation kit (Sigma). 
Approximately 300-1000ng/µl of purified plasmid was obtained from a 300ml 
bacterial culture corresponding to each vector.  
4.1.2 Antibody over-expression in HEK293 EBNA cells  
The full-length anti-LRP/LR IgG1-iS18 and anti-CD19 IgG1-HD37 antibodies were 
successfully produced in HEK293 EBNA cells by co-transfecting the vector encoding 
for the heavy and the light chains in the ratio 53ng:36ng (HC:LC). HEK293 EBNA 
cells are human embryonic kidney 293 cells stably transformed with the EBV EBNA-
1 gene. This cell line was chosen since the vectors encoding for the heavy and light 
chains have EBV oriP, resulting in an increased protein expression in the presence of 
EBNA-152. Transfection was performed using the calcium phosphate precipitation 
method. Supernatants were collected over 24-hour and 48-hour periods, following 
transfection as described in the Materials and Methods section.  1 litre of culture 
medium was collected after each transient transfection and this was then purified.  
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4.1.3 Purification and detection of IgG1-iS18 and IgG1-HD37   
1 litre of supernatant collected from transiently transfected HEK293 EBNA cells was 
filtered by Protein A Sepharose™ affinity chromatography. The protein A is able to 
bind immunoglobulin’s through the interaction with the fc region of the heavy chain. 
The antibodies that had bound to the column were eluted using a low pH buffer and 
the collected fractions (2ml each) were then analyzed by 12% SDS-PAGE. The full- 
length antibody has a molecular weight of approximately 150kDa. Under reducing 
conditions, the disulphide bridges linking the heavy and light chains are disrupted and 
this will give rise to the appearance of 2 bands on the SDS-PAGE gel, at 50kDa 
(heavy chain) and 25kDa (light chain), respectively (Figure 12). Both IgG1-iS18 and 
IgG1-HD37 were successfully over-expressed in HEK293 EBNA cells. A total yield 
of 1µg/µl purified IgG1-iS18 and 1,5µg/µl purified IgG1-HD37 were obtained per 1l 
of culture medium, this was then utilized in subsequent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Biochemical analysis of IgG1-iS18 and IgG1-HD37 over-pressed in HEK293 
EBNA cells co-transfected with vectors encoding for the heavy and light chains. SDS-PAGE 
and Coomassie blue staining of the IgG1-iS18 following Protein A Sepharose™ purification 
and dialysis (lanes 1, 2, 3), and IgG1-HD37 (lanes 4, 5, 6) purified from HEK293 EBNA cells 
after protein A sepharose purification and dialysis. The heavy chain can be seen at 50kDa and 
the light chain at around 25kDa.   
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4.1.4 Dialysis of IgG1-iS18 and IgG1-HD37 
 
Dialysis is not only used to remove low molecular weight contaminants, such as salt, 
but also for buffer exchange prior to or after different chromatographic steps, in this 
case it was employed following Protein A Sepharose™ affinity chromatography. The 
molecular weight of IgG is 150kDa and that of the unwanted salts ranges between 
2000 and 5000Da. A micro-dialysis unit with a cut off at 5000Da retained the 
antibody as the salts diffused out.  
 
   
4.1.5 Characterization of IgG1-iS18 
 
The purified antibody was then used in a Western Blot analysis to test its binding 
capability and specificity. It was found to successfully bind to the 37kDa LRP in 
several neoplastic cell lines, also, the secondary goat anti-human antibody was able to 
bind to the already bound IgG1-iS18 and upon application of the substrate 
fluorescence was visible (Figure 13).  
 
 
 
 
Figure 13: Western Blotting detection of 37kDa LRP from various neoplastic cell lysates by 
purified IgG1-iS18 antibody. In each lane, the same amount of total protein was loaded; 
lysates were separated by SDS-PAGE and transferred to a PVDF membrane. The marker is 
shown and in lane 1 SW480, lane 2 LNCaP, lane 3 HeLa, lane 4 A549, lane 5 HT-1080 and 
lane 6 NIH/3T3.  
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4.2 LRP levels 
4.2.1 Cell surface LRP levels    
Tumorigenic cell lines reveal a significantly increased cell surface LRP/LR level 
compared to the non-tumorigenic cell line NIH/3T3   
A key factor in the process of metastasis is the interaction of the LRP/LR located on 
the surface of neoplastic cells, and Laminin-1. Therefore the cell surface levels of 
LRP/LR were investigated in order to ascertain if an increased LRP/LR level would 
result in an increased invasive potential. Cell surface levels of LRP/LR on the various 
neoplastic cell lines, as well as the negative control NIH/3T3 cell line, was detected 
using Fluorescent Activated Cell Scanning (FACS™) employing the LRP/LR specific 
antibody IgG1-iS18 coupled to FITC. The results shown in Figure 15 clearly indicate 
the binding of the LRP-specific antibody IgG1-iS18 to the cell surface 37kDa LRP. 
The shift that can be seen between the black and the gray curves indicates that a 
change in fluorescence intensity was detected. This shift is due to the fluorescence of 
the FITC that is bound to the LRP-specific antibody IgG1-iS18.  FACS™ analysis 
revealed a 1.11 significant fold increase in LRP/LR levels on HT-1080 (88%) (Fig. 
14a), in comparison to NIH/3T3 (79%) (Fig.14b). A significantly increased level of 
LRP/LR was noted in all neoplastic cell lines with a 1.25 fold higher level on A549 
cells (98%) (Fig. 14c) and SW480 cells (99%) (Fig. 14d), a 1.223 fold higher level on 
HeLa cells (Fig. 14e), a 1.24 fold higher level on LNCaP (Fig. 14f), and a 1.19 fold 
higher level on the non-invasive MCF-7 cells (Fig.14g).     
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Figure 14: Detection of 37kDa/67kDa LRP/LR levels on the surface of various cell lines. 
Fluorescence Activated Cell Scanning (FACS™) analysis was performed using a FITC 
coupled IgG1-iS18 antibody on (a) HT-1080, (b) NIH/3T3, (c) A549, (d) SW480, (e) HeLa, 
(f) LNCaP and (g) MCF-7 cells. The gray curve represents the control with no antibody while 
the black curve represents the cells incubated with the fluorescence labelled antibody. Cells 
were not permeabilized. The double peak seen in (a), (b) and (g) could be attributed to non-
specific binding with the second peak possibly indicative of some antibody binding well 
while others not at all. This could mean that there is a different characteristic in some of the 
cells of that type that causes a small percentage to bind to the fluorophore, or that there is a 
certain limit to the percentage of FITC-coupled antibody that can bind in any one sample. 
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Figure 15: Bar chart of surface LRP/LR levels on HT-1080, A549, SW480, HeLa, LNCaP, 
MCF-7 and NIH/3T3 cells analyzed by FACS™. Neoplastic cell lines displayed significantly 
higher cell surface LRP/LR levels compared to NIH/3T3 cells. Data extracted from Figure 14. 
Data are representative of three independent experiments comprising cells from different 
cultures.   
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4.2.2 Total LRP levels  
 
Total LRP/LR levels of neoplastic cell lines  
 
To investigate a possible correlation between the level of LRP/LR with the invasive 
potential of tumorigenic cell lines, the total LRP/LR level, including cytoplasmic and 
cell membrane LRP/LR was determined by semi-quantitative Western Blot analysis. 
The protein concentration of cell lysates derived from the various cell lines was 
ascertained using a BCA-assay. The amount of protein loaded was standardized to 
30µg of total cellular protein.  Western Blot analysis was then performed and the anti-
LRP/LR specific IgG1-iS18 was employed as the primary antibody with a goat anti-
human POD coupled secondary antibody. As a loading control ß-actin was also 
employed and a rabbit anti-mouse antibody specific for ß-actin was used as the 
secondary antibody (see Materials and Methods). It was found that the stripping of the 
membrane was ineffective and therefore two different membranes were used to detect 
each protein. i.e. one membrane was incubated with the LRP/LR specific antibody 
IgG1-iS18 and the other with the mouse anti-ß-actin antibody.  The 37kDa LRP was 
detected and the blots shown in figure 16, however, the 67kDa form could not be 
detected in the cell lysates using Western Blotting and the IgG1-iS18 specific 
antibody (Data not shown). Lysates were collected from 3 different cultures for each 
cell line. 
 
 
 
 
 
 
 
Figure 16: Analysis of the relative expression of the total LRP/LR levels in several neoplastic 
cell lines detected with IgG1-iS18, which binds to the 37kDa LRP and the anti-ß-actin 
antibody specific for the 42kDa ß-actin (acting as loading control). 30µg of total cellular 
protein was loaded.   
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Figure 17: Graphic illustration of the relative expression of the total LRP levels of neoplastic 
cell lines detected by IgG1-iS18 primary antibody and goat anti-human POD secondary 
antibody by Western Blotting quantified using densitometry. Percentages represent the 
Integrated Optical Density (IOD). Each was carried out in triplicate with cells from different 
cultures.   
 
As can be seen in figure 17, all neoplastic cell lines contained significantly higher 
levels of LRP in comparison to the non-tumorigenic control NIH/3T3 cell line. The 
most significant increase in total LRP levels was noted in the SW480 (human colon 
adenocarcinoma) cell line, concurrent with the highest cell surface LRP also noted in 
this cell line. Interestingly, the LNCaP (human prostate carcinoma) cell line, although 
showing a significant increase in LRP level in comparison to the NIH/3T3, seems to 
contain the least LRP amongst the neoplastic cell lines (Figure 17).    
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4.3 Cell adhesion potential  
Neoplastic cell adhesion to Laminin-1 impeded by LRP/LR specific antibody IgG1-iS18 
 
The adhesion to Laminin-1 is vital for the invasion of neoplastic cells. The potential 
of the anti-LRP/LR antibody IgG1-iS18 in the blockage of this binding was 
determined using adhesion assays. Neoplastic cells were incubated with IgG1-iS18 
and IgG1-HD37 control antibody (0.2 µg/µl). Cells were transferred to a 96-well 
plate, either coated with Laminin-1 or uncoated, for 1 hour at 37°C. Optimization of 
these parameters was done by researching previous studies done and repeating 
experiments. Buffer was used in place of antibody in the no antibody control samples.  
 Attached cells were stained and absorbance measured at 550 nm. Attachment to the 
uncoated plate (w/o Laminin-1 control) represents the background binding. The 
absorbance of the stain present correlates with the percentage of laminin-attached 
cells.  A significantly decreased adhesion potential is noted in all neoplastic cell lines 
except the MCF-7 cell line (p= 0.4129), upon application of IgG1-iS18 (medium red) 
in comparison to the no antibody control (deep red) (Fig. 18). The control cell line, 
mouse embryonic fibroblasts NIH/3T3 displayed a 28% reduction in adhesion 
potential following incubation with IgG1-iS18 antibody (p= 0.0076). The positive 
control cell line HT-1080 showed a similar decrease in adhesion potential 21% (p= 
0.0064). LnCap cells showed a 20% reduction (p= 0.0225) and HeLa cells a 14% 
reduction (p= 0.0323). The most noteworthy reduction was seen in SW480 cells with 
a 74% reduction (p= 0.0007) and a 48% reduction in adhesion was noted in A549 
cells (p= 0.0134) (Table 10). Furthermore, the control IgG1-HD37 (light red) 
antibody has no significant effect on the adhesion potential (p > 0.1663).  Data are 
representative of experiments carried out in triplicate.  
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Figure 18: Adhesion to Laminin-1significantly impeded by anti-LRP/LR specific antibody 
IgG1-iS18 following an incubation of 1 hour on Laminin-1 coated plates at 37°C. Cells were 
applied on to a 96-well place, either coated with Laminin-1 or uncoated. After the attached 
cells were washed, they were stained with crystal violet and absorbance measured at 570nm. 
Cells attached to uncoated wells represent the background binding.  
 
Table 10: Percentage reduction in adhesion potential in various neoplastic cell lines 
Cell line  % Reduction in adhesion potential  P- value 
HT-1080 21% 0.0064 ** 
A549 48% 0.0134 * 
MCF-7 0% 0.1540  
HeLa 14% 0.0323 * 
SW480 74% 0.0007 *** 
LNCaP 20% 0.0225 * 
Note: the % in reduction in adhesion potential refers to the difference in adhesion 
potential between the samples without antibody compared to cells incubated with 
IgG1-iS18 antibody.  
P-values calculated using two-tailed Students t-test with a 95% confidence interval. 
Please refer to 3.8 for details of statistical evaluation.  
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4.4 Invasive potential   
4.4.1 Determination of cell invasive potential of selected neoplastic cell lines 
 
Prior to investigating the effect of LRP/LR specific antibodies on the invasive 
potential, we had to determine the invasive potential of the neoplastic cell lines HT-
1080, A549, HeLa, SW480 and LNCaP. These particular cell lines were chosen as 
they are described as having an invasive potential. The non-invasive MCF-7 cell line 
served as a negative control since it is known to be non-invasive53. Even in the 
presence of a chemo-attractant the MCF-7 cells did not invade the Matrigel™, 
therefore the extent to which the other neoplastic cells had invaded was compared to 
the MCF-7 cell line and the statistical evaluation was done in accordance with this. In 
previous studies, the tumorigenic fibrosarcoma cell line HT-1080 was analyzed and 
its invasive potential determined to be greater than that of the non-tumorigenic mouse 
embryonic fibroblast cell line NIH/3T333. This study confirmed that the HT-1080 are 
in fact invasive following an 18 hour incubation on a polymerized Matrigel™.  HT-
1080 cells showed a significantly increased in the invasive potential of 78% in 
comparison to the MCF-7 cell line (p= 0.0001). The A549 and HeLa cells displayed a 
similar trend with increased invasive potentials of 83% and 85%, respectively (p= 
0.0001). In the same experimental setup, LNCaP was also found to be significantly 
more invasive than the MCF-7 cell line with a 82% increase, however the most 
invasive of the neoplastic cell lines was the SW480 (human colon adenocarcinoma) 
cell line with a 86% increased invasive potential (p = 0.0001) (Figure 19) (Table 11). 
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Figure 19: Tumorigenic cells reveal a significantly increased invasive potential in comparison 
to non-invasive MCF-7 cells after 18 hour incubation on a polymerized Matrigel™ at 37°C, 
5% CO2. The absorption of invaded cells stained with toluidine blue was measured at 620nm.  
 
 
Table 11: Tumorigenic cell lines with their invasive behaviour and invasive potential 
relative to the MCF-7 cell line   
Cell line  Cell type  Invasive 
potential 
% Invasive 
potential 
relative to 
MCF-7 
MCF-7 Human breast adenocarcinoma cells Non-invasive  - 
HT-1080 Human fibrosarcoma cells  Invasive  60% 
A549 Human lung carcinoma cells Invasive  81% 
HeLa Human cervix carcinoma cells  Invasive  86% 
LNCaP Human prostate carcinoma cells  Invasive  65% 
SW480 Human colon adenocarcinoma cells Invasive  95% 
 Note: Invasive potentials were determined using the absorbance measured at 620nm. A 
percentage was then determined by calculating the difference between the respective cell line 
and the invasive potential value of MCF-7 and then dividing by the highest value (SW480 set 
to 100%).    
 
 
 
  45 
4.4.2 IgG1-iS18 significantly decreased the invasive potential in neoplastic cell lines 
 
Invasion assays were performed using the aforementioned neoplastic cell lines and the 
ability of the IgG1-iS18 antibody in hindering cell invasion was determined. These 
cell lines were pre-incubated with 0.2µg/µl of the full-length anti-LRP/LR specific 
antibody IgG1-iS18 and the anti-CD19 control antibody IgG1-HD37. Once again the 
invasive potentials of cells that were not pre-incubated with antibody was determined 
as in 5.4.1 ensure accuracy and show if the control antibody had an effect on invasion. 
It was found that the invasive potential of the HT-1080 cells in the absence of 
antibody did not differ significantly to those of the HT-1080 cells incubated with the 
control antibody IgG1-HD37 (p = 0.1520). A significant decrease in invasion of 44% 
was noted in HT-1080 cells upon application of the IgG1-iS18 antibody when 
compared to the sample containing no antibody (p= 0.0030) (Figure 20). A549 cell 
invasion was impeded significantly by 33% (p = 0.0127) with the use of IgG1-iS18 in 
contrast to the no antibody control. In comparison to the no antibody sample the 
means of the control antibody IgG1-HD37 did not differ significantly (p = 0.5495) in 
A549 cells (Fig. 22). A similar trend was seen with HeLa cells with a very significant 
reduction of 57% in the invasion following incubation with the IgG1-iS18 antibody (p 
= 0.0002) in comparison to the sample containing no antibody (Fig. 21). Invasion was 
significantly hindered by 38% after pre-incubation of LNCaP cells with the anti-
LRP/LR antibody in comparison to the no antibody control as well the IgG1-HD37 
control (p = 0.0003) (Fig. 23). The most significant decrease in invasion potential 
upon application of IgG1-iS18 was seen in SW480 cells demonstrating a 91% 
reduction (p = 0.0001) (Fig. 24), with invasive behaviour remaining unaffected by the 
negative control antibody. Overall, it was observed that the anti-LRP/LR antibody 
significantly reduced the invasive capability in the various neoplastic cell lines (Table 
12).  Representative photographs clearly illustrated the decrease in the amount of 
toluidine blue stain that was retained by cells that had invaded (Figure 25).   
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Figure 20: Decreased invasive potential of HT-1080 human fibrosarcoma cells by 0.2µg/µl of 
IgG1-iS18 after a 10 minute pre-incubation with the antibodies and 18 incubation on the 
polymerized Matrigel™ at 37°C, 5% CO2. The stain retained by invaded cells was extracted 
and measured at 620nm. Background invasion was deducted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Decreased invasive potential of HeLa human cervix carcinoma cells by 0.2µg/µl of 
IgG1-iS18 after a 10 minute pre-incubation with the antibodies and 18 incubation on the 
polymerized Matrigel™ at 37°C, 5% CO2. The stain retained by invaded cells was extracted 
and measured at 620nm. Background invasion was deducted.       
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Figure 22: Decreased invasive potential of A549 human lung carcinoma cells by 0.2µg/µl of 
IgG1-iS18 after a 10 minute pre-incubation with the antibodies and 18 incubation on the 
polymerized Matrigel™ at 37°C, 5% CO2. The stain retained by invaded cells was extracted 
and measured at 620nm. Background invasion was deducted. 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Decreased invasive potential of LNCaP human prostate carcinoma cells by 
0.2µg/µl of IgG1-iS18 after a 10 minute pre-incubation with the antibodies and 18 incubation 
on the polymerized Matrigel™ at 37°C, 5% CO2. The stain retained by invaded cells was 
extracted and measured at 620nm. Background invasion was deducted. 
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Figure 24: Decreased invasive potential of SW480 human colon adenocarcinoma cells by 
0.2µg/µl of IgG1-iS18 after a 10 minute pre-incubation with the antibodies and 18 incubation 
on the polymerized Matrigel™ at 37°C, 5% CO2. The stain retained by invaded cells was 
extracted and measured at 620nm. Background invasion was deducted.     
Table 12: Invasion into Matrigel™ matrix is significantly impeded by IgG1-iS18 
antibody 
 
Cell line:  % Reduction in invasion P-value  
HT-1080 44% 0.0030 *** 
HeLa 57% 0.0002 *** 
A549 33% 0.0127 * 
LNCaP 38% 0.0003 *** 
SW480 91% 0.0001 ***  
Note: The % reduction in invasion is the difference in invasive potential between cells 
without antibody compared to cells incubated with IgG1-iS18 antibody.   
P-values calculated using two-tailed Students t-test with a 95% confidence interval. 
Please refer to 3.8 for details of statistical evaluation.    
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Figure 25: Cell invasion through a Matrigel™ matrix is inhibited by anti-LRP specific 
antibody IgG1-iS18. Representative photographs of invaded cells stained toluidine blue. 
These images were taken after the dye was extracted from cells and the absorbance of this 
was then measured at 620nm. The staining correlates with the number of cells that was able to 
invade. a.) As can be seen from the shade of blue, the IgG1-iS18 incubated cells had an 
impaired ability to invade in both the HeLa and A549 cell lines. (lighter blue). b.) A similar 
observation was made with the LNCaP cell line and c.) SW480 cell line where there is a 
distinct difference in the amount of dye present and therefore fewer invaded cells upon 
application of IgG1-iS18.  
b. 
c. 
a. 
c. 
HeLa 
A549 
IgG1‐HD37    IgG1‐iS18    IgG1‐HD37    IgG1‐iS18 
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CHAPTER FIVE – DISCUSSION     
In this study we examined the effect of the anti-LRP/LR specific antibody IgG1-iS18 
on cell invasion and cell adhesion in various neoplastic cell lines in order to ascertain 
its potential as a therapeutic tool for the treatment of metastatic cancer. For this to be 
achieved, the full-length IgG1-iS18 antibody and the control antibody IgG1-HD37 
were initially produced by the over-expression in a mammalian cell system and then 
characterized by Western Blotting analysis. The antibody was then applied in 
subsequent assays with additional antibody kindly supplied by Affimed Therapeutics.  
 
5.1 Antibody development  
Monoclonal antibodies (MAb’s) currently represent over 30% of biopharmaceuticals 
used in clinical trials and approximately 60-70% of all pharmaceuticals based on 
recombinant protein are produced in mammalian cell systems54. HEK293 (human 
embryonic kidney) cells, and other cultivated mammalian systems, have become 
preferred choices for the production of recombinant proteins for clinical application 
due their ability to allow for correct protein folding, assembly and post-translational 
modifications. Further advances in this specific system include the HEK293 cells 
being stably transfected with the EBNA-1 gene, which enhances the protein 
expression when the plasmid DNA contains EBV oriP. Particularly, in the last decade, 
immunotherapy has received immense attention, however, in some instances 
monoclonal antibodies have limited application in human clinical trials due to their 
immunogenicity. With the use of modern genetic engineering techniques we are now 
able to produce chimeric mouse/human as well as completely human antibodies55. 
The development of single-chain antibodies, which are composed of variable regions 
of the heavy and light chains joined by a short peptide linker, were found to have a 
short half-life of approximately 12 hours in the blood. In order to overcome this 
limitation of the scFv, full-length antibodies were created by Affimed Therapeutics 
Heidelberg. Apart from the longer half-life, these enhanced full-length antibodies 
have a higher affinity for LRP/LR combined with the avid effect caused by bivalent 
binding.  
  51 
 
 
5.2 Process of metastasis 
In order for tumor metastasis to occur the cells comprising the primary tumor must 
first acquire the ability to proteolyse the ECM, concomitant with the breakage of 
existing attachments, thereafter the extension of pseudopodia as well as translocation 
will result in these cells entering the circulatory system. The final step in the process 
is the invasion and colonization of distant organ sites56. The hypothesis that the 
metastatic potential of tumor cells correlates with enzymatic degradation of the 
basement membrane type IV collagen is supported by several studies57.   
 
Crossing of the basement membrane by neoplastic cells is a vital step in the process of 
metastasis41. As a major basement membrane glycoprotein, Laminin-1 plays a crucial 
role in cell attachment, migration, proliferation, growth and differentiation, 
elucidating its function in tumor invasion and metastasis. In vitro as well as in vivo 
studies have demonstrated that the attachment of tumor cells to Laminin-1 augments 
tumorigenic and metastatic potential58.  The 37kDa/67kDa LRP/LR receptor was first 
isolated from tumor cells36 and since has been found to be over-expressed in several 
cancer cell lines58.  The receptor is thought to play a crucial role during cell invasion 
and therefore in the metastasis due to its interaction with Laminin-141 and 
consequently the degradation of the basement membrane.                
 
5.3 LRP/LR, cell surface LRP and total LRP levels    
A full-length gene encodes for the 37kDa Laminin Receptor Precursor. To date, it is 
unknown how the 67kDa LR originates from the 37kDa LRP3. Although LRP/LR is a 
non-integrin receptor it acts as an integrin-accessory molecule by stabilizing the 
binding of laminin to cell surface integrins. Due to this involvement with integrins, 
which are the primary mediators of cell adhesion, the potential effect that blocking 
LRP/LR could have is quite evident. Integrins also play a role in signal transduction 
to the nucleus following interactions between cells as well as cell-ECM interactions36. 
Perhaps, the anti-LRP/LR specific antibody impedes this process resulting in a 
decreased adhesion potential.  
             
  52 
 
LRP/LR offers two binding sites for Laminin-1, a peptide G sequence (aa 161-180) 
and another at the carboxy terminus (aa 205-229)3. Due to LRP spanning the lipid 
bilayer as well as having the C-terminus situated in the extracellular space and a 
cytoplasmic N-terminus, it can be classified as a type II transmembrane protein. Both 
the laminin binding domains are found in the extracellular space where3, upon 
interaction with Laminin-1, it boosts tumor cell invasion and aggressiveness, induces 
further expression of the 67kDa LR as well as activates proteolytic enzymes that 
consequently lead to extracellular matrix degradation38. The interaction between the 
67kDa form and Laminin-1 causes the up-regulation of various processes that 
ultimately results in an enhanced ability to invade distal tissue via the hematogenous 
route. An increased expression of the 67kDa form in conjunction with the further 
activation of proteolytic enzymes contributes to this enhancement33. 
 
The level of LRP/LR on the surface of these cell lines was ascertained using FACS™ 
analysis in order to determine the degree of correlation between LRP/LR levels and 
invasion and adhesion potential. FACS™ analysis revealed that HT-1080 cells have 
increased cell surface levels of LRP/LR in comparison to NIH/3T3 with a 1.1 fold 
higher level, confirming findings of previous studies33. The control mouse embryonic 
fibroblasts (NIH/3T3) have a decreased invasive potential when compared to the 
human fibrosarcoma cell line (HT-1080). This result was expected since NIH/3T3 
cells are known to be non-tumorigenic and non-invasive59. All neoplastic cell lines 
displayed significantly higher levels of cell surface LRP/LR including the non-
invasive MCF-7 cell line. The greatest increase in LRP/LR levels was found in A549 
and SW480 cells. Furthermore, not only did the SW480 cells reveal significantly 
increased levels of LRP/LR, they also proved to have the highest invasive potential. 
By calculating the Pearson’s correlation co-efficient between the levels of LRP/LR 
and the respective invasive potentials, it was found to be 0.53 (Table 13), indicating 
that the correlation is positive thus there is a positive relationship. Therefore, we 
propose that in most instances a higher LRP/LR level correlates with an increased 
invasive potential.   
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Table 13: Pearson’s correlation coefficient values    
 
5.4 Surface and total LRP levels appear not to be an accurate indication of 
invasive potential  
Despite a correlation between cell surface LRP/LR levels and invasive potential, this 
is not always the case since the MCF-7 cell line is an exception. Interestingly, with a 
relatively high cell surface LRP level illustrated by FACS™ analysis (93%), and total 
LRP/LR level demonstrated using Western Blotting (81%), it was found to have an 
extremely low and almost undetectable invasive potential. The MCF-7 breast 
carcinoma cell line was established from the pleural effusion of a patient with breast 
adenocarcinoma60 and was found to contain estrogen receptors. A possible 
explanation for the unexpected behavior displayed in this study could be that these 
cells require estrogens to proceed with invasion and thereby express a great malignant 
character61. Studies have shown that 17ß-estradiol is able to stimulate the invasive and 
metastatic potential of tumorigenic cells. Traversing though an artificially synthesized 
basement membrane in vitro was also enhanced62, and this trend was also 
demonstrated in nude mice upon which the introduction of 17ß-estradiol resulted in 
increased tumor formation as well as distant metastasis63. 
 
5.5 Optimizing invasion assay  
Manipulation of the Matrigel™ matrix concentration, polymerization times, as well as 
the duration of incubation of cells on the matrix was well achieved and experiments 
were done prior to the actual study in order to optimize these parameters. It was found 
that the most suitable concentration of Matrigel™ was 1mg/ml, a polymerization time 
of 6 hours and an incubation time of 18 hours was ideal. A way in which the invasion 
assay could be improved further is with the use of Growth Factor Reduced Matrigel™ 
Matrix. This form of Matrigel™ is purified and characterized to a greater extent than 
the Matrigel™ used in this study. It contains a reduced the level of a variety of growth 
factors except for TGF-beta which may be bound to collagen IV. The major 
components of Matrigel™, such as laminin, collagen IV and entactin (nidogen) are 
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conserved by the purification process, however the level of heparan sulfate 
proteoglycan is reduced by 40-50%.  
 
5.6 Effect of IgG1-iS18 antibody on invasion and adhesion  
The Pearson’s correlation co-efficient of the adhesion potential and the invasion 
potential was found to be 0.77 (Table 13), indicating a definite positive relationship, 
further proving that adhesion is a pre-requisite for invasion. The results presented in 
this study clearly indicate the considerable decrease in adhesion potential in important 
cancer types following incubation with the anti-LRP/LR specific antibody. A 
reduction of up to 74% in adhesion potential was observed in SW480 cells and a 
noteworthy 48% decline in A-549 cells, respectively.  The significant effect of the 
IgG1-iS18 antibody on the invasion potential can be attributed to changes on a 
molecular level, which include the blockage of adhesion. Application of IgG1-iS18 
had a significant effect on 5 major cancer types concomitant with a reduction in the 
invasive potential. A remarkable decrease of 91% of the invasive potential of SW480 
cells and a convincing reduction of 57% invasive potential in HeLa cells opens new 
possibilities of hindering the invasion of neoplastic cells. The molecular mechanisms 
underlying blockage of invasion includes the blockage of adhesion. The significant 
reduction in invasion and adhesion of human fibrosarcoma (HT-1080), human cervix 
carcinoma (HeLa), human lung carcinoma (A549), human prostrate carcinoma 
(LNCaP) and human colon adenocarcinoma (SW480), by the antibody IgG1-iS18 
suggest that this macromolecule might act as a therapeutic tool for the treatment of 
many metastatic cancer types targeting the Laminin-1 and LRP/LR interaction.  
 
Previous studies demonstrated that the application of anti-LRP/LR tools resulted in 
the significant hindrance of invasive potential of human fibrosarcoma (HT-1080) 
cells. siRNA’s directed against LRP mRNA achieved a significant reduction in 
invasion by  37%33. Moreover, other approaches that included the pentosan 
polysulfate SP-54 as well as the heparan mimetic HM2602, significantly blocked the 
invasion of HT-1080 cells by 35% and 20% respectively33. In the same study it was 
found that the single chain antibody scFv iS18 was able to reduce invasion by 37% 
and that the full-length antibody IgG1-iS18, that was the focus of this study, displayed 
a 38% reduction in invasion33. The reduced invasive behavior of human fibrosarcoma 
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cells (HT-1080) noted due to application of anti-LRP/LR tools, in conjunction with 
the cell adhesion assay results were analyzed. It was proposed that this impaired 
invasive potential could be attributed to the obstruction of the adhesion of LRP/LR 
(expressed on the cell surface) to Laminin-1.    
5.7 Antibody activity 
It has also been suggested that the binding of the IgG1-iS18 antibody to LRP/LR may 
influence the Mitogen-Activated Protein Kinase (MAPK) signaling cascade since it is 
induced by an interaction with Laminin-1. Serine and threonine are particular protein 
kinases of interest due to their influential role in tumor metastasis. Other possible 
mechanisms by which the anti-LRPL/LR specific antibody IgG1-iS18 functions could 
be by the sterical blockage of either one or both of the laminin binding sites situated 
at aa161-180 and aa205-229 Figure 3. The same effect could be achieved by directly 
occupying these laminin-binding sites, however, the exact mechanism of the antibody 
action is yet to be elucidated.  
 
In the present study, tumorigenic cell lines incubated with the anti-LRP/LR antibody 
IgG1-iS18 demonstrated a significantly decreased ability to attach to Laminin-1 and 
to traverse Matrigel™ coated inserts. These findings are in agreement with other 
studies elucidating the role of the 67kDa laminin receptor in attachment to Laminin-1 
and invasion of tumor cells33.   
 
5.8 Outlook  
Matrigel™ is a heterogenous composition that can be used to simulate the basement 
membrane since it is prepared from solubilized basement membrane extracted from 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells. This cell line is ideal since it is 
known to be rich in extracellular matrix proteins such as laminin, collagen IV, 
heparan sulfate proteoglycans and entactin64. Several other compounds that occur 
naturally in the EHS tumor include TGF-ß, epidermal growth factor, insulin-like 
growth factor, fibroblast growth factor and tissue plasminogen activator65. Matrigel™ 
also contains various other proteins and although present in low concentrations they 
could possibly influence the results obtained.  Overall the exact composition of the 
matrix is not provided and only a total protein concentration is given (10mg/ml), 
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therefore, the amount of laminin present is unknown and could vary between batches. 
In this study, the batch of Matrigel™ was consistent throughout the many invasion 
assays, however results could differ if experiments were to be repeated with a 
different batch due to the varying concentrations of ECM proteins. Alternatives to a 
Matrigel™ Matrix include chicken chorioallantoic membrane, mouse urinary bladder, 
human amnion, other placental membranes and lens capsule of the eye66. Perhaps 
further studies could be done using other matrices derived from these sources to 
confirm results; also, the exact composition of the matrix should be determined to 
ensure accuracy, in particular the concentration of laminin.  
 
Seeing as only the 5 major cancer types were used in this study, it would be 
interesting to apply the anti-LRP/LR specific antibody to other cancer types, such as 
liver, pancreatic, gastric and invasive breast cancer combating the top ten cancer types 
worldwide.  
 
Since the anti-LRP/LR specific antibody IgG1-iS18 was able to significantly reduce 
adhesion and invasion in vitro, and is also known to have a half-life of approximately 
3 weeks in blood, it serves as a viable option a therapeutic to be tested in vivo. 
Currently several mouse models are available, using A549 human lung carcinoma 
cells and HT-1080 human fibrosarcoma cells to induce tumors and metastasis 
formation67. Also, a mouse model bearing human prostate cancer in which the 
tumorigenic cells were inoculated under the skin has been used to demonstrate the 
anti-tumor effect of siRNA’s68. There have been claims that transgenic tumor models, 
or subcutaneously growing human tumors induced in immuno-deficient mice cannot 
be a precise representation of clinical cancer, and therefore does not accurately 
display metastatic activity and cannot be used to assess drug sensitivity efficiently. 
Alternatives such as orthotopic implantations allow for the direct transplantation of 
fragments of intact human tumors into the equivalent organ in immuno-deficient mice 
and therefore represents clinical cancer69. These models in conjunction with in vivo 
imaging technology serve as a bridge linking pre-clinical and clinical research and 
drug development, allowing for effective testing of potential anti-metastatic therapies 
including the anti-LRP/LR specific antibody IgG1-iS18.  
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7. APPENDIX  
APPENDIX A  
Cell line data sheets:  
HT-1080 
 
DSMZ no.:  ACC 315 
Species:  human (Homo sapiens) 
Cell type:  fibrosarcoma 
Origin:  established from the biopsy from a fibrosarcoma of a 35-year-old 
Caucasian man in 1972; patient did not receive any chemo- or 
radiotherapy 
Depositor:  Dr. M. Wirth, GBF, Braunschweig, Germany 
Biosafety:  Level 1 
  
DSMZ Cell Culture Data: 
Morphology:  epithelial-like adherent cells growing as monolayers 
Medium:  90% Dulbecco's MEM + 10% h.i. FBS 
Subculture:  split confluent culture about 1:10 every 3 days using trypsin/EDTA; 
seed out at ca. 1-2 x 106 cells/80 cm2 + 7-10 ml medium 
Incubation:  at 37 °C with 5-10% CO2 
Doubling time: ca. 30 hours 
Harvest:  cell harvest of ca. 25 x 106 cells/175 cm2 
Storage:  frozen with 70% medium, 20% FBS, 10% DMSO at about 1-2 x 106 
cells/ampoule 
DSMZ Scientific Data: 
Mycoplasma:  negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Immunology:  cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, 
cytokeratin-18 +, cytokeratin-19 -, desmin -, endothel -, EpCAM -, 
GFAP -, neurofilament -, vimentin + 
Fingerprint:  multiplex PCR of minisatellite markers revealed a unique DNA profile 
Species:  confirmed as human with IEF of AST, LDH, NP 
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, 
HHV-8 -, HIV -, HTLV-I/II , SMRV - 
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NIH/3T3 
 
DSMZ no.: ACC 59 
Species: murine (mouse, Swiss mouse) (Mus musculus) 
Cell type: embryo 
Origin: contact-inhibited NIH Swiss mouse embryo; used in DNA transfection 
assays 
Depositor: Dr. H. Hauser, GBF, Braunschweig, Germany 
Biosafety: level 1 
  
DSMZ Cell Culture Data: 
Morphology: fibroblast, adherent monolayer 
Medium: 90% Dulbecco's MEM (4.5 g/L glucose) + 10% h.i. FBS (or NCS) 
Subculture: do not allow culture to become completely confluent; split culture at 
1:10 every 4 to 6 days using trypsin/EDTA; seed out at ca. 1 x 104 
cells/cm2 
Incubation: at 37 °C with 5-10% CO2 
Doubling time: ca. 20 hours 
Harvest: cell harvest of about 8 x 104 cells/cm2 
Storage: frozen with 70% medium, 20% FBS, 10% DMSO at about 0.7 x 106 
cells/ampoule 
  
DSMZ Scientific Data: 
Mycoplasma: contamination was eliminated with Mycoplasma Removal Agent, then 
negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Species:  confirmed as mouse with IEF of AST, MDH, PEP B and by species
   PCR 
Viruses: ELISA: reverse transcriptase negative; PCR: SMRV – 
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SW480 
 
DSMZ no.: ACC 313 
Species: human (Homo sapiens) 
Cell type: colon adenocarcinoma 
Origin: established from the tumor of a 50-year-old Caucasian man with colon 
adenocarcinoma (grade 4, Duke class B) 
Depositor: Dr. H. Kirchner, Medical School Hannover, Hannover, Germany 
Biosafety: level 1 
  
DSMZ Cell Culture Data: 
Morphology:  endothelial-like adherent cells, mostly bipolar with microvilli growing 
in monolayers 
Medium: 90-95% RPMI 1640 + 5-10% h.i. FBS 
Subculture: split confluent culture 1:5 to 1:10 once a week using trypsin/EDTA; 
seed out at about 1.0 x 106 cells/80 cm2; an 80 cm2 culture flask 
becomes confluent within 1 week 
Incubation:  at 37 °C with 5% CO2 
Doubling time: 25-30 hours 
Harvest: cell harvest of about 10-15 x 106 cells/80 cm2 
Storage: frozen with 70% medium, 20% FBS, 10% DMSO at about 3 x 106 
cells/ampoule 
  
DSMZ Scientific Data: 
Mycoplasma:  negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Immunology:  cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, 
cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, 
GFAP -, neurofilament -, vimentin + 
Fingerprint:  multiplex PCR of minisatellite markers revealed a unique DNA profile 
Species:  confirmed as human with IEF of AST, LDH, MDH 
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, 
HIV -, HTLV-I/II -, SMRV – 
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HeLa 
DSMZ no.: ACC 57 
Species: human (Homo sapiens) 
Cell type: cervix carcinoma 
Origin: established from the epitheloid cervix carcinoma of a 31-year-old 
black woman in 1951; later diagnosis changed to adenocarcinoma; first 
aneuploid, continuously cultured human cell line 
Depositor:  obtained from ATCC (CCL 2), Rockville, Maryland, USA 
Biosafety: level 1 
Risk assessment: The cell line is infected with papilloma virus type 18 (HPV-18). An activation and transmission of the HPV-18 
during handling of the cell line is improbable. The cell line is categorized biosafety level 1.  
DSMZ Cell Culture Data: 
Morphology: epithelial-like cells growing in monolayers 
Medium: 90% MEM (with Earle's salts) + 10% h.i. FBS + 2 mM L-glutamine + 
non-essential amino acids (cells also grow well in 90-95% RPMI 1640 
+ 5-10% h.i. FBS) 
Subculture:  split confluent culture 1:4 to 1:6 every 3-5 days using trypsin/EDTA; 
cells reach confluence quickly; seed out at ca. 1-2 x 106 cells/80 cm2 
Incubation: at 37 °C with 5% CO2 
Doubling time: ca. 48 hours 
Harvest: cell harvest of ca. 5-15 x 106 cells/175 cm2 
Storage: frozen with 70% medium, 20% FBS, 10% DMSO at about 1 x 106 
cells/ampoule 
 DSMZ Scientific Data: 
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Immunology:  cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 +, 
cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM -, 
GFAP -, HMB-45 -, neurofilament -, vimentin + 
Fingerprint: multiplex PCR of minisatellite markers revealed a unique DNA  
Species:  confirmed as human with IEF of G6PD, MDH, NP 
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, 
HHV-8 -, HIV -, HPV +, HTLV-I/II -, SMRV - 
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LNCaP 
 
DSMZ no.: ACC 256 
Species: human (Homo sapiens) 
Cell type: prostate carcinoma 
Origin: established from the left supraclavicular lymph node metastasis from a 
50-year-old man with prostate carcinoma in 1977; cells were described 
to be androgen-sensitive 
Depositor: Prof. M. Motta, Universita di Milano, Milan, Italy 
Biosafety: level 1 
 
DSMZ Cell Culture Data: 
Morphology: adherent fibroblastoid cells growing in aggregates and as single cells 
Medium: 80% RPMI 1640 + 20% h.i. FBS 
Subculture: split semi-confluent culture 1:4 once a week using trypsin/EDTA 
(occasionally cells can be detached by tapping); seed out at ca. 1-2 x 
106 cells/25 cm2; after thawing and trypsinization cells may need 1-2 
days to become adherent again; due to the strong cell aggregation, it 
might be difficult to determine an exact cell titer 
Incubation: at 37 °C with 5% CO2 
Doubling time: about 60 hours 
Harvest: cell harvest of about 10-15 x 106 cells/80 cm2 flask 
Storage: frozen with 70% medium, 20% FBS, 10% DMSO at about 3 x 106 
cells/ampoule 
 DSMZ Scientific Data: 
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Immunology:  cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, 
cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, 
GFAP -, neurofilament -, vimentin - 
Fingerprint: multiplex PCR of minisatellite markers revealed a unique DNA profile 
Species: confirmed as human with IEF of AST, MDH 
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, 
HHV-8 -, HIV -, HTLV-I/II -, SMRV – 
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A-549 
DSMZ no.: ACC 107 
Species: human (Homo sapiens) 
Cell type: lung carcinoma 
Origin: established from an explanted lung tumor which was removed from a 
58-year-old Caucasian man in 1972; cells were described to induce 
tumors in athmyic mice and to synthesize lecithin 
Depositor: Dr. J. Wehland, GBF, Braunschweig, Germany 
Biosafety: level 1 
  
DSMZ Cell Culture Data: 
Morphology: epithelial cells, growing adherently as monolayer 
Medium: 90% Dulbecco's MEM + 10% h.i. FBS 
Subculture: split confluent cultures 1:5 to 1:10 every 4-7 days using trypsin/EDTA; 
cells grow easily; seed out at ca. 1-2 x 106 cells/80 cm2 + 10 ml 
medium 
Incubation: at 37 °C with 5% CO2 
Doubling time: ca. 40 hours 
Harvest: about 20 x 106 cells/175 cm2 
Storage: frozen with 70% medium, 20% FBS, 10% DMSO at about 0.5 x 106 
cells/ampoule 
  
DSMZ Scientific Data: 
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Immunology: cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, 
cytokeratin-18 +, cytokeratin-19 -, desmin - , endothel - , EpCAM -, 
GFAP - , neurofilament - , vimentin + 
Fingerprint: multiplex PCR of minisatellite markers revealed a unique DNA profile 
Species: confirmed as human with IEF of MDH, NP 
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, 
HHV-8 -, HIV -, HTLV-I/II -, SMRV – 
 
 
  68 
MCF-7 
 
DSMZ no.: ACC 115 
Species: human (Homo sapiens) 
Cell type: breast adenocarcinoma 
Origin: established from the pleural effusion of a 69-year-old Caucasian 
woman with metastatic mammary carcinoma (after radio- and hormone 
therapy) in 1970; cells were described of being positive for 
cytoplasmic estrogen receptors and having the capability to form 
domes 
Depositor: obtained from ATCC (HTB 22), Rockville, Maryland, USA 
Biosafety: level 1 
  
DSMZ Cell Culture Data: 
Morphology: epithelial-like cells growing as monolayers 
Medium: 90% RPMI 1640 + 10% h.i. FBS + MEM non-essential amino acids + 
1 mM sodium pyruvate + 10 µg/ml human insulin 
Subculture: split confluent culture 1:2 to 1:4 every 2-6 days using trypsin/EDTA; 
seed out at ca. 0.1-0.2 x 105 cells/cm2 
Incubation: at 37 °C with 5% CO2 
Doubling time: ca. 50 hours (range 30-72 hours) 
Harvest:  about 50-60 x 106 cells/175 cm2 
Storage:  frozen with 70% medium, 20% FBS, 10% DMSO at about 0.8 x 106 
cells/ampoule  
DSMZ Scientific Data: 
Mycoplasma:  negative in DAPI, microbiological culture, RNA hybridization, PCR 
assays 
Immunology:  cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, 
cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, 
GFAP -, neurofilament -, vimentin - 
Fingerprint: multiplex PCR of minisatellite markers revealed a unique DNA profile 
Species: confirmed as human with IEF of AST, MDH Viruses:  ELISA: reverse transcriptase negative; PCR: EBV ‐, HBV ‐, HCV ‐, HHV‐8 ‐, HIV ‐, HTLV‐I/II ‐, SMRV – 
